Impax Laboratories (IPXL) 10-Q 11 May 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	1-May-15
Document and Entity Information [Abstract]
Entity Registrant Name	IMPAX LABORATORIES INC
Document Type	10-Q
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding		71,702,203
Amendment Flag	FALSE
Entity Central Index Key	1003642
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Well-known Seasoned Issuer	Yes
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1

Consolidated_Balance_Sheets_Un

Consolidated Balance Sheets (Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
ASSETS
Cash and cash equivalents	$163,093,000	$214,873,000
Short-term investments		199,983,000
Accounts receivable, net	180,310,000	146,490,000
Inventory, net	121,120,000	80,570,000
Deferred income taxes	80,095,000	54,825,000
Prepaid expenses and other current assets	53,501,000	33,710,000
Total current assets	598,119,000	730,451,000
Property, plant and equipment, net	215,591,000	188,169,000
Other assets	66,351,000	64,455,000
Deferred income taxes	127,000	41,837,000
Intangible assets, net	750,025,000	26,711,000
Goodwill	152,050,000	27,574,000
Total assets	1,782,263,000	1,079,197,000
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current portion of long-term debt	18,741,000
Accounts payable	49,344,000	31,976,000
Accrued expenses	146,507,000	110,470,000
Accrued profit sharing and royalty expenses	26,122,000	15,346,000
Current portion of deferred revenue	3,923,000	907,000
Total current liabilities	244,637,000	158,699,000
Long-term debt	398,609,000
Deferred revenue	3,176,000	3,403,000
Deferred tax liability	202,967,000
Other liabilities	38,548,000	29,218,000
Total liabilities	887,937,000	191,320,000
Commitments and contingencies (Notes 10 and 18)
Stockholders’ equity:
Preferred stock, $0.01 par value, 2,000,000 shares authorized, no shares outstanding at March 31, 2015 and December 31, 2014
Common stock, $0.01 par value, 90,000,000 shares authorized and 71,872,067 and 71,470,802 shares issued at March 31, 2015 and December 31, 2014, respectively	719,000	714,000
Additional paid-in capital	373,980,000	364,103,000
Treasury stock - 243,729 shares	-2,157,000	-2,157,000
Accumulated other comprehensive loss	-3,109,000	-6,009,000
Retained earnings	524,893,000	531,226,000
Total stockholders’ equity	894,326,000	887,877,000
Total liabilities and stockholders’ equity	$1,782,263,000	$1,079,197,000

Consolidated_Balance_Sheets_Un1

Consolidated Balance Sheets (Unaudited) (Parentheticals) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Preferred Stock, par value (in Dollars per share)	$0.01	$0.01
Preferred Stock, shares authorized	2,000,000	2,000,000
Preferred Stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$0.01	$0.01
Common stock, shares authorized	90,000,000	90,000,000
Common stock, shares issued	71,872,067	71,470,802
Treasury stock, shares	243,729	243,729

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenues:
Revenues	$143,096,000	$118,718,000
Cost of revenues	83,862,000	61,096,000
Gross profit	59,234,000	57,622,000
Operating expenses:
Research and development	14,962,000	21,741,000
Patent litigation expense	960,000	2,173,000
Selling, general and administrative	50,160,000	25,477,000
Total operating expenses	66,082,000	49,391,000
(Loss) income from operations	-6,848,000	8,231,000
Other (loss) income, net	-166,000	76,000
Interest income	284,000	388,000
Interest expense	-3,975,000	-65,000
(Loss) income before income taxes	-10,705,000	8,630,000
(Benefit) provision for income taxes	-4,372,000	2,205,000
Net (loss) income	-6,333,000	6,425,000
Net (loss) income per share:
Basic (in Dollars per share)	($0.09)	$0.09
Diluted (in Dollars per share)	($0.09)	$0.09
Weighted average common shares outstanding:
Basic (in Shares)	68,967,875	67,702,296
Diluted (in Shares)	68,967,875	69,938,872
Impax Generics [Member]
Revenues:
Revenues	128,741,000	109,141,000
Impax Specialty Pharma [Member]
Revenues:
Revenues	$14,355,000	$9,577,000

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (Unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Net (loss) income	($6,333)	$6,425
Currency translation adjustments	2,900	-2,435
Comprehensive (loss) income	($3,433)	$3,990

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net (loss) income	($6,333)	$6,425
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:
Depreciation and amortization	10,442	8,015
Charge for licensing agreement		2,000
Intangible asset impairment charge		2,876
Provision for inventory reserves	-822	1,952
Accretion of interest income on short-term investments	-81	-223
Deferred income taxes – net and uncertain tax positions	-668	-2,879
Tax impact related to the exercise of employee stock options and restricted stock	-660	-920
Deferred revenue and product costs, net	2,517
Recognition of deferred revenue	-227	-1,050
Accrued profit sharing and royalty expense	20,652	10,608
Payments of profit sharing and royalty expense	-15,334	-11,537
Share-based compensation expense	6,488	4,386
Changes in certain assets and liabilities:
Accounts receivable	21,637	-6,528
Inventory	-4,880	-6,527
Prepaid expenses and other assets	-10,048	976
Accounts payable and accrued expenses	-1,631	-26,163
Other liabilities	2,605	1,513
Net cash provided by (used in) operating activities	23,657	-17,076
Cash flows from investing activities:
Payment for acquisition, net of cash acquired	-697,183
Purchase of short-term investments		-133,754
Maturities of short-term investments	200,064	101,443
Purchases of property, plant and equipment	-4,223	-9,782
Proceeds from sale of assets	4,000
Payments for licensing agreements and acquisitions		-2,000
Net cash used in investing activities	-497,342	-44,093
Cash flows from financing activities:
Proceeds from issuance of term loan, gross	435,000
Payment of deferred financing fees	-17,831
Tax impact related to the exercise of employee stock options and restricted stock	660	920
Proceeds from exercise of stock options and ESPP	3,065	5,977
Net cash provided by financing activities	420,894	6,897
Effect of exchange rate changes on cash and cash equivalents	1,011	-968
Net decrease in cash and cash equivalents	-51,780	-55,240
Cash and cash equivalents, beginning of period	214,873	184,612
Cash and cash equivalents, end of period	$163,093	$129,372

Supplemental_Cash_Flow_Informa

Supplemental Cash Flow Information	3 Months Ended
	Mar. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Cash Flow, Supplemental Disclosures [Text Block]	Supplemental disclosure of non-cash investing and financing activities:
		Three Months Ended
	(in $000's)	March 31,		March 31,
		2015		2014
	Cash paid for interest	$	2,317	$	1
	Cash paid for income taxes	$	6,615	$	21,024
	Accrued vendor invoices of approximately $1,326,000 and $4,165,000 at March 31, 2015 and 2014, respectively, are excluded from the purchase of property, plant, and equipment and the change in accounts payable and accrued expenses and prepaid and other assets. Depreciation expense was $5,381,000 and $4,973,000 for the three months ended March 31, 2015 and 2014, respectively.

Note_1_The_Company_Basis_of_Pr

Note 1 - The Company & Basis of Presentation	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. THE COMPANY & BASIS OF PRESENTATION
	Impax Laboratories, Inc. (“Impax” or the “Company”) is a specialty pharmaceutical company that focuses on developing, manufacturing, marketing and distributing generic and branded pharmaceutical products. The Company has two reportable segments, referred to as “Impax Generics” and “Impax Specialty Pharma.” The Impax Generics division focuses on a broad range of therapeutic areas, including products having technically challenging drug-delivery mechanisms or unique product formulations. In addition to developing solid oral dosage products, the Impax Generic division’s portfolio includes alternative dosage form products, primarily through alliance and collaboration agreements with third parties. The Company’s Impax Specialty Pharma division is focused on the development and promotion, through the Company’s specialty sales force, of proprietary branded pharmaceutical products for the treatment of central nervous system (“CNS”) disorders and other select specialty segments. As described in detail below, in March 2015, the Company renamed its operating and reporting structure into its current structure; prior to such time, the Impax Generics division was referred to as “Global Pharmaceuticals” and the Impax Specialty Pharma division was referred to as “Impax Pharmaceuticals.”
	Acquisition of Tower Holdings, Inc. (“Tower”) and Lineage Therapeutics Inc. (“Lineage”)
	On October 8, 2014, the Company entered into an agreement to acquire Tower, including its operating subsidiaries CorePharma LLC (“CorePharma”) and Amedra Pharmaceuticals LLC (“Amedra Pharmaceuticals”), and Lineage for a purchase price of $700 million in cash, subject to customary adjustments for working capital, net debt and transaction expenses (the “Transaction”). The privately-held companies specialized in the development, manufacture and commercialization of complex generic and branded pharmaceutical products. On March 9, 2015, Impax completed the Transaction. For additional information on the acquisition and the related financing of the acquisition, refer to “Note 8 – Business Acquisitions” and “Note 12 – Debt.”
	In connection with the Transaction, the Company recorded an accrual for severance and related termination costs of $2.4 million in the three month period ended March 31, 2015 related to the elimination of approximately 10 positions at the acquired companies. As of March 31, 2015, approximately $0.1 million of such costs had been paid and significantly all of the remaining severance and termination costs are expected to be paid by December 31, 2015.
	Revised Operating and Reporting Structure
	In connection with the closing of the Transaction, Impax renamed the operating and reporting structure of its two divisions into Impax Generics and Impax Specialty Pharma. Impax Generics includes the Company’s legacy Global Pharmaceuticals business as well as the acquired CorePharma and Lineage businesses. Impax Specialty Pharma includes the legacy Impax Pharmaceuticals business as well as the acquired Amedra Pharmaceuticals business.
	Impax Generics develops, manufactures, sells, and distributes generic pharmaceutical products primarily through the following four sales channels: the “Impax Generics” sales channel, for generic pharmaceutical prescription products the Company sells directly to wholesalers, large retail drug chains, and others; the “Private Label” sales channel, for generic pharmaceutical over-the-counter (“OTC”) and prescription products the Company sells to unrelated third-party customers who, in turn, sell the product to third parties under their own label; the “Rx Partner” sales channel, for generic prescription products sold through unrelated third-party pharmaceutical entities under their own label pursuant to alliance agreements; and the “OTC Partner” sales channel, for generic pharmaceutical OTC products sold through unrelated third-party pharmaceutical entities under their own labels pursuant to alliance and supply agreements. Revenues from the “Impax Generics” sales channel and the “Private Label” sales channel are reported under the caption “Impax Generics sales, net” in “Note 19 – Supplementary Financial Information.” The Company also generates revenue in Impax Generics from research and development services provided under a joint development agreement with another unrelated third-party pharmaceutical company, and reports such revenue under the caption “Other Revenues” in “Note 19 – Supplementary Financial Information.” The Company provides these services through the research and development group in Impax Generics. Revenues from the “OTC Partner” sales channel are also reported under the caption “Other Revenues” in “Note 19 – Supplementary Financial Information.”
	Impax Specialty Pharma is engaged in the development of proprietary brand pharmaceutical products that the Company believes represent improvements to already-approved pharmaceutical products addressing CNS disorders and other select specialty segments. Impax Specialty Pharma currently has one internally developed branded pharmaceutical product, RYTARY® (IPX066), an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and/or manganese intoxication, which was approved by the FDA on January 7, 2015 and which the Company began marketing in the United States (“U.S.”) in April 2015. The Company has also filed the required documents for a Market Authorization Application to the European Medicines Agency (EMA) for IPX066 on November 5, 2014 and the filing was accepted by the EMA on November 26, 2014. The Company is currently also seeking to identify a licensing partner for the development and commercialization of IPX066 in countries outside of the U.S. Impax Specialty Pharma is also engaged in the sale and distribution of four other branded products, the more significant include Zomig® (zolmitriptan) products, indicated for the treatment of migraine headaches, under the terms of a Distribution, License, Development and Supply Agreement (“AZ Agreement”) with AstraZeneca UK Limited (“AstraZeneca”) in the United States and in certain U.S. territories, and Albenza®, indicated for the treatment of tapeworm infections. Revenues from Impax-labeled branded products are reported under the caption “Impax Specialty Pharma sales, net” in “Note 19 – Supplementary Financial Information.” Finally, the Company generates revenue in Impax Specialty Pharma from research and development services provided under a development and license agreement with another unrelated third-party pharmaceutical company, and reports such revenue under the caption “Other Revenues” in “Note 19 – Supplementary Financial Information.” Impax Specialty Pharma also has a number of product candidates that are in varying stages of development.
	In California, the Company utilizes a combination of owned and leased facilities mainly located in Hayward. The Company’s primary properties in California consist of a leased office building used as the Company’s corporate headquarters, in addition to five properties it owns, including a research and development center facility and a manufacturing facility. Additionally, the Company leases three facilities in Hayward, utilized for additional research and development, administrative services, equipment storage and quality assurance support. In Pennsylvania, the Company owns a packaging, warehousing, and distribution center located in Philadelphia and leases a facility in New Britain used for sales and marketing, finance, and administrative personnel, as well as providing additional warehouse space. In connection with the closing of the Transaction, the Company acquired leased manufacturing and warehousing facilities in Middlesex, New Jersey and leased office space utilized for administrative services in Horsham, Pennsylvania. Outside the United States, in Taiwan, Republic of China (“R.O.C.”), the Company owns a manufacturing facility.
	The accompanying unaudited interim consolidated financial statements of the Company, have been prepared based upon United States Securities and Exchange Commission (“SEC”) rules permitting reduced disclosure for interim periods, and include all adjustments necessary for a fair presentation of statements of operations, statements of comprehensive income, statements of cash flows, and financial condition for the interim periods shown, including normal recurring accruals and other items, noted below. While certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to SEC rules and regulations, the Company believes the disclosures are adequate to make the information presented not misleading. The unaudited interim consolidated financial statements of the Company include the accounts of the operating parent company, Impax Laboratories, Inc., its wholly owned subsidiaries, including Impax Laboratories (Taiwan), Inc., Impax Laboratories USA, LLC, ThoRx Laboratories, Inc., Impax International Holding, Inc., Impax Holdings, LLC, Impax Laboratories (Netherlands) BV and Impax Laboratories (Netherlands) CV, Lineage Therapeutics Inc. and Tower Holdings, Inc., including operating subsidiaries CorePharma, LLC, Amedra Pharmaceuticals, LLC, Mountain, LLC and Trail Services, Inc., in addition to an equity investment in Prohealth Biotech, Inc. (“Prohealth”), in which the Company held a 57.54% majority ownership interest at March 31, 2015. All significant intercompany accounts and transactions have been eliminated.
	The unaudited results of operations and cash flows for the interim period are not necessarily indicative of the expected results of the Company’s operations for any other interim period or for the full year ending December 31, 2015. The unaudited interim consolidated financial statements and footnotes should be read in conjunction with the consolidated financial statements and footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 as filed with the SEC, wherein a more complete discussion of significant accounting policies and certain other information can be found.
	The preparation of financial statements in conformity with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on complex judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant judgments are employed in estimates used in determining values of tangible and intangible assets, legal contingencies, tax assets and tax liabilities, fair value of share-based compensation related to equity incentive awards issued to employees and directors, and estimates used in applying the Company’s revenue recognition policy including those related to accrued chargebacks, rebates, product returns, Medicare, Medicaid, and other government rebate programs, shelf-stock adjustments, and the timing and amount of deferred and recognized revenue and deferred and amortized product manufacturing costs related to alliance and collaboration agreements. Actual results may differ from estimated results.
	In the normal course of business, the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business, covering a wide range of matters, including, among others, patent litigation, and product and clinical trial liability. In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 450, “Contingencies,” the Company records accrued loss contingencies when it is probable a liability has been incurred and the amount of loss can be reasonably estimated. The Company, in accordance with FASB ASC Topic 450, does not recognize gain contingencies until realized.

Note_2_Revenue_Recognition

Note 2 - Revenue Recognition	3 Months Ended
	Mar. 31, 2015
Revenue Recognition [Abstract]
Revenue Recognition [Text Block]	2. REVENUE RECOGNITION
	The Company recognizes revenue when the earnings process is complete, which under SEC Staff Accounting Bulletin No. 104, Topic No. 13, “Revenue Recognition” (“SAB 104”), is when revenue is realized or realizable and earned, there is persuasive evidence a revenue arrangement exists, delivery of goods or services has occurred, the sales price is fixed or determinable, and collectability is reasonably assured.
	The Company accounts for revenue arrangements with multiple deliverables in accordance with FASB ASC Topic 605-25, revenue recognition for arrangements with multiple elements, which addresses the determination of whether an arrangement involving multiple deliverables contains more than one unit of accounting. A delivered item within an arrangement is considered a separate unit of accounting only if both of the following criteria are met:
		●	the delivered item has value to the customer on a stand-alone basis; and
		●	if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially in the control of the vendor.
	Under FASB ASC Topic 605-25, if both of the criteria above are not met, then separate accounting for the individual deliverables is not appropriate. Revenue recognition for arrangements with multiple deliverables constituting a single unit of accounting is recognized generally over the greater of the term of the arrangement or the expected period of performance, either on a straight-line basis or on a modified proportional performance basis.
	The Company accounts for milestones related to research and development activities in accordance with FASB ASC Topic 605-28, milestone method of revenue recognition. FASB ASC Topic 605-28 allows for the recognition of consideration, which is contingent on the achievement of a substantive milestone, in its entirety in the period the milestone is achieved. A milestone is considered to be substantive if all of the following criteria are met: the milestone is commensurate with either: (1) the performance required to achieve the milestone, or (2) the enhancement of the value of the delivered items resulting from the performance required to achieve the milestone; the milestone relates solely to past performance; and, the milestone is reasonable relative to all of the deliverables and payment terms within the agreement.
	Impax Generics sales, net, and Impax Specialty Pharma sales, net
	Impax Generics sales, net and Impax Specialty Pharma sales, net include revenue recognized related to shipments of generic and branded pharmaceutical products to the Company’s customers, primarily drug wholesalers and retail chains. Gross sales revenue is recognized at the time title and risk of loss passes to the customer, which is generally when product is received by the customer. Impax Generics and Impax Specialty Pharma revenue, net may include deductions from the gross sales price related to estimates for chargebacks, rebates, distribution service fees, returns, shelf-stock, and other pricing adjustments. The Company records an estimate for these deductions in the same period when the revenue is recognized. A summary of each of these deductions is as follows:
	Chargebacks
	The Company has agreements establishing contract prices for certain products with certain indirect customers, such as managed care organizations, hospitals and government agencies who purchase products from drug wholesalers. The contract prices are lower than the prices the customer would otherwise pay to the wholesaler, and the price difference is referred to as a chargeback, which generally takes the form of a credit memo issued by the Company to reduce the invoiced gross selling price charged to the wholesaler. An estimated accrued provision for chargeback deductions is recognized at the time of product shipment. The primary factors considered when estimating the provision for chargebacks are the average historical chargeback credits given, the mix of products shipped, and the amount of inventory on hand at the major drug wholesalers with whom the Company does business. The Company also monitors actual chargebacks granted and compares them to the estimated provision for chargebacks to assess the reasonableness of the chargeback reserve at each quarterly balance sheet date.
	Rebates
	The Company maintains various rebate programs with its customers in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. The rebates generally take the form of a credit memo to reduce the invoiced gross selling price charged to a customer for products shipped. An estimated accrued provision for rebate deductions is recognized at the time of product shipment. The primary factors the Company considers when estimating the provision for rebates are the average historical experience of aggregate credits issued, the mix of products shipped and the historical relationship of rebates as a percentage of total gross product sales, the contract terms and conditions of the various rebate programs in effect at the time of shipment, and the amount of inventory on hand at the major drug wholesalers with whom the Company does business. The Company also monitors actual rebates granted and compares them to the estimated provision for rebates to assess the reasonableness of the rebate reserve at each quarterly balance sheet date.
	Distribution Service Fees
	The Company pays distribution service fees to several of its wholesaler customers related to sales of its Impax products. The wholesalers are generally obligated to provide the Company with periodic outbound sales information as well as inventory levels of the Company’s products held in their warehouses. Additionally, the wholesalers have agreed to manage the variability of their purchases and inventory levels within specified days on hand limits. An accrued provision for distribution service fees is recognized at the time products are shipped to wholesalers.
	Returns
	The Company allows its customers to return product if approved by authorized personnel in writing or by telephone with the lot number and expiration date accompanying any request and if such products are returned within six months prior to or until twelve months following the products’ expiration date. The Company estimates and recognizes an accrued provision for product returns as a percentage of gross sales based upon historical experience. The product return reserve is estimated using a historical lag period, which is the time between when the product is sold and when it is ultimately returned and estimated return rates which may be adjusted based on various assumptions including changes to internal policies and procedures, changes in business practices, and commercial terms with customers, competitive position of each product, amount of inventory in the wholesaler supply chain, the introduction of new products, and changes in market sales information. The Company also considers other factors, including significant market changes which may impact future expected returns, and actual product returns. The Company monitors actual returns on a quarterly basis and may record specific provisions for returns it believes are not covered by historical percentages.
	Shelf-Stock Adjustments
	Based upon competitive market conditions, the Company may reduce the selling price of certain Impax Generics products. The Company may issue a credit against the sales amount to a customer based upon their remaining inventory of the product in question, provided the customer agrees to continue to make future purchases of product from the Company. This type of customer credit is referred to as a shelf-stock adjustment, which is the difference between the original selling price and the revised lower sales price, multiplied by an estimate of the number of product units on hand at a given date. Decreases in selling prices are discretionary decisions made by the Company in response to market conditions, including estimated launch dates of competing products and declines in market price. The Company records an estimate for shelf-stock adjustments in the period it agrees to grant such a credit memo to a customer.
	Medicaid and Other Government Pricing Programs
	As required by law, the Company provides a rebate on drugs dispensed under the Medicaid program, Medicare Part D, TRICARE, and other United States government pricing programs. The Company determines its estimated government rebate accrual primarily based on historical experience of claims submitted by the various states and other jurisdictions and any new information regarding changes in the various programs which may impact the Company’s estimate of government rebates. In determining the appropriate accrual amount, the Company considers historical payment rates and processing lag for outstanding claims and payments. The Company records estimates for government rebates as a deduction from gross sales, with corresponding adjustment to accrued liabilities.
	Cash Discounts
	The Company offers cash discounts to its customers, generally 2% of the gross selling price, as an incentive for paying within invoice terms, which generally range from 30 to 90 days. An estimate of cash discounts is recorded in the same period when revenue is recognized.
	Rx Partner and OTC Partner
	The Rx Partner and OTC Partner contracts include revenue recognized under alliance and collaboration agreements between the Company and unrelated third-party pharmaceutical companies. The Company has entered into these alliance agreements to develop marketing and/or distribution relationships with its partners to fully leverage its technology platform.
	The Rx Partners and OTC Partners alliance agreements obligate the Company to deliver multiple goods and/or services over extended periods. Such deliverables include manufactured pharmaceutical products, exclusive and semi-exclusive marketing rights, distribution licenses, and research and development services. In exchange for these deliverables, the Company receives payments from its agreement partners for product shipments and research and development services, and may also receive other payments including royalty, profit sharing, upfront, and periodic milestone payments. Revenue received from the alliance agreement partners for product shipments under these agreements is not subject to deductions for chargebacks, rebates, product returns, and other pricing adjustments. Royalty and profit sharing amounts the Company receives under these agreements are calculated by the respective agreement partner, with such royalty and profit share amounts generally based upon estimates of net product sales or gross profit which include estimates of deductions for chargebacks, rebates, product returns, and other adjustments the alliance agreement partners may negotiate with their respective customers. The Company records the alliance agreement partner's adjustments to such estimated amounts in the period the agreement partner reports the amounts to the Company.
	The Company applies the updated guidance of ASC 605-25 “Multiple Element Arrangements” to the Strategic Alliance Agreement with Teva Pharmaceuticals Curacao N.V., a subsidiary of Teva Pharmaceutical Industries Limited (“Teva Agreement”). The Company looks to the underlying delivery of goods and/or services which give rise to the payment of consideration under the Teva Agreement to determine the appropriate revenue recognition. The Company initially defers consideration received as a result of research and development-related activities performed under the Teva Agreement. The Company recognizes deferred revenue on a straight-line basis over the Company’s expected period of performance of such services. The Company recognizes revenue received as a result of the manufacture and delivery of products under the Teva Agreement at the time title and risk of loss passes to the customer which is generally when product is received by Teva. The Company recognizes profit share revenue in the period earned.
	OTC Partner revenue is related to agreements with Pfizer Inc. (formerly Wyeth) and L. Perrigo Company with respect to the supply of over-the-counter pharmaceutical products. The OTC Partner sales channel is no longer a core area of the business, and the over-the-counter pharmaceutical products the Company sells through this sales channel are older products which are only sold to Pfizer and Perrigo, and which are currently sold at a loss, on a fully absorbed basis. The Company is currently only required to manufacture the over-the-counter pharmaceutical products under its agreements with Pfizer and Perrigo. The Company recognizes profit share revenue in the period earned.
	Research Partner
	The Research Partner contracts include revenue recognized under development agreements with unrelated third-party pharmaceutical companies. The development agreements generally obligate the Company to provide research and development services over multiple periods. In exchange for this service, the Company received upfront payments upon signing of each development agreement and is eligible to receive contingent milestone payments, based upon the achievement of contractually specified events. Additionally, the Company may also receive royalty payments from the sale, if any, of a successfully developed and commercialized product under one of these development agreements. The Company recognizes revenue received from the provision of research and development services, including the upfront payment and the milestone payments received before January 1, 2011 on a straight-line basis over the expected period of performance of the research and development services. The Company recognizes revenue received from the achievement of contingent research and development milestones after January 1, 2011 in the period such payment is earned. Royalty fee income, if any, will be recognized by the Company in the period when the revenue is earned.
	Shipping and Handling Fees and Costs
	Shipping and handling fees related to sales transactions are recorded as selling expense.

Note_3_Recent_Accounting_Prono

Note 3 - Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2015
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	3. RECENT ACCOUNTING PRONOUNCEMENTS
	In May 2014, the FASB issued updated guidance regarding the accounting for and disclosures of revenue recognition. The update provides a single comprehensive model for accounting for revenue from contracts with customers. The model requires that revenue recognized reflect the actual consideration to which the entity expects to be entitled in exchange for the goods or services defined in the contract, including in situations with multiple performance obligations. This guidance will be the same for both U.S. GAAP and International Financial Reporting Standards (IFRS) and is effective for annual and interim periods beginning after December 15, 2016. The Company is currently evaluating the effect that this guidance may have on its consolidated financial statements.
	In April 2015, the FASB issued updated guidance on the presentation requirements for debt issuance costs and debt discount and premium. The update requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the updated guidance. The updated guidance is effective for annual and interim periods beginning after December 15, 2015 and early adoption is permitted for financial statements that have not been previously issued. The Company adopted this guidance in the three month period ended March 31, 2015.

Note_4_Investments

Note 4 - Investments	3 Months Ended
	Mar. 31, 2015
Investments Schedule [Abstract]
Investment [Text Block]	4. INVESTMENTS
	Investments consist of commercial paper and corporate bonds. The Company’s policy is to invest in only high quality “AAA-rated” or investment-grade securities. Investments in debt securities are accounted for as “held-to-maturity” and are recorded at amortized cost, which approximates fair value, generally based upon observable market values of similar securities. The Company has historically held all investments in debt securities until maturity, and has the ability and intent to continue to do so. All of the Company’s investments have remaining contractual maturities of less than 12 months and are classified as short-term. Upon maturity, the Company uses a specific identification method.
	There were no short-term investments outstanding as of March 31, 2015. A summary of short-term investments as December 31, 2014 is as follows:
	(in $000’s)	Amortized		Gross		Gross			Fair
	31-Dec-14	Cost		Unrecognized		Unrecognized			Value
				Gains		Losses
	Commercial paper	$	68,972	$	17	$	--		$	68,989
	Corporate bonds		131,011		--		(101	)		130,910
	Total short-term investments	$	199,983	$	17	$	(101	)	$	199,899
	During the three month period ended March 31, 2015, the Company liquidated its entire portfolio of short-term investments to fund the purchase price of its March 9, 2015 acquisition of Tower and Lineage.

Note_5_Accounts_Receivable

Note 5 - Accounts Receivable	3 Months Ended
	Mar. 31, 2015
Receivables [Abstract]
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	5. ACCOUNTS RECEIVABLE
	The composition of accounts receivable, net is as follows:
	(in $000’s)	March 31,			December 31,
		2015			2014
	Gross accounts receivable	$	453,067		$	287,362
	Less: Rebate reserve		(188,548	)		(88,812	)
	Less: Chargeback reserve		(66,453	)		(43,125	)
	Less: Other deductions		(17,756	)		(8,935	)
	Accounts receivable, net	$	180,310		$	146,490
	A roll forward of the rebate and chargeback reserves activity for the three months ended March 31, 2015 and the year ended December 31, 2014 is as follows:
	(in $000’s)	March 31,			December 31,
	Rebate reserve	2015			2014
	Beginning balance	$	88,812		$	88,449
	Acquired balances		78,226			--
	Provision recorded during the period		85,262			260,747
	Credits issued during the period		(63,752	)		(260,384	)
	Ending balance	$	188,548		$	88,812
	(in $000’s)	March 31,			December 31,
	Chargeback reserve	2015			2014
	Beginning balance	$	43,125		$	37,066
	Acquired balances		25,260			--
	Provision recorded during the period		132,168			487,377
	Credits issued during the period		(134,100	)		(481,318	)
	Ending balance	$	66,453		$	43,125
	Other deductions include allowance for uncollectible amounts and cash discounts. The Company maintains an allowance for doubtful accounts for estimated losses resulting from amounts deemed to be uncollectible from its customers, with such allowances for specific amounts on certain accounts. The Company had an allowance for uncollectible amounts of $926,000 and $515,000 at March 31, 2015 and December 31, 2014, respectively.

Note_6_Inventory

Note 6 - Inventory	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	6. INVENTORY
	Inventory is stated at the lower of cost or market. Cost is determined using a standard cost method, and the cost flow assumption is first in, first out (“FIFO”) flow of goods. Standard costs are revised annually, and significant variances between actual costs and standard costs are apportioned to inventory and cost of goods sold based upon inventory turnover. Costs include materials, labor, quality control, and production overhead. Inventory is adjusted for short-dated, unmarketable inventory equal to the difference between the cost of inventory and the estimated value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by the Company, additional inventory write-downs may be required. Consistent with industry practice, the Company may build pre-launch inventories of certain products which are pending required approval from the FDA and/or resolution of patent infringement litigation, when, in the Company’s assessment, such action is appropriate to increase the commercial opportunity and FDA approval is expected in the near term and/or the litigation will be resolved in the Company’s favor. The Company accounts for all costs of idle facilities, excess freight and handling costs, and wasted materials (spoilage) as a current period charge in accordance with GAAP.
	Inventory, net of carrying value reserves at March 31, 2015 and December 31, 2014 consisted of the following:
	(in $000’s)	March 31,		December 31,
		2015		2014
	Raw materials	$	48,716	$	34,681
	Work in process		5,568		2,447
	Finished goods		77,982		55,102
	Total inventory		132,266		92,230
	Less: Non-current inventory		11,146		11,660
	Total inventory-current	$	121,120	$	80,570
	In connection with the Transaction, the Company acquired $34.0 million in inventory, including approximately $3.0 million of non-currrent inventory included in Other Non-current Assets.
	Inventory carrying value reserves were $31,473,000 and $25,639,000 at March 31, 2015 and December 31, 2014, respectively. The carrying value of unapproved inventory less reserves was $5,934,000 and $7,312,000 at March 31, 2015 and December 31, 2014, respectively.
	The Company recognizes pre-launch inventories at the lower of its cost or the expected net selling price. Cost is determined using a standard cost method, which approximates actual cost, and assumes a FIFO flow of goods. Costs of unapproved products are the same as approved products and include materials, labor, quality control, and production overhead. When the Company concludes that FDA approval is expected within approximately six months for a drug product candidate, the Company may begin to schedule manufacturing process validation studies as required by the FDA to demonstrate the production process can be scaled up to manufacture commercial batches. Consistent with industry practice, the Company may build quantities of unapproved product inventory pending final FDA approval and/or resolution of patent infringement litigation, when, in the Company’s assessment, such action is appropriate to increase its commercial product opportunity, and FDA approval is expected in the near term, and/or the litigation will be resolved in the Company’s favor. The capitalization of unapproved pre-launch inventory involves risks, including, among other items, FDA approval may not occur; approvals may require additional or different testing and/or specifications than used for unapproved inventory, and in cases where the unapproved inventory is for a product subject to litigation, the litigation may not be resolved or settled in the Company’s favor. If any of these risks materialize and the launch of the unapproved product inventory is delayed or prevented, then the net carrying value of unapproved inventory may be partially or fully reserved. Generally, the selling price of a generic pharmaceutical product is at a discount from the corresponding brand product selling price. Typically, a generic drug is easily substituted for the corresponding brand product, and once a generic product is approved, the pre-launch inventory is typically sold within the next three months. If the market prices become lower than the product inventory carrying costs, then the pre-launch inventory value is reduced to such lower market value. If the inventory produced exceeds the estimated market acceptance of the generic product and becomes short-dated, a carrying value reserve will be recorded. In all cases, the carrying value of the Company's pre-launch product inventory is lower than the respective estimated net selling prices.
	To the extent inventory is not scheduled to be utilized in the manufacturing process and/or sold within 12 months of the balance sheet date, it is included as a component of other non-current assets. Amounts classified as non-current inventory consist of raw materials, net of valuation reserves. Raw materials generally have a shelf life of approximately three to five years, while finished goods generally have a shelf life of approximately two years.

Note_7_Property_Plant_and_Equi

Note 7 - Property, Plant and Equipment	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	7. PROPERTY, PLANT AND EQUIPMENT
	Property, plant and equipment, net consisted of the following:
	(in $000’s)	March 31,			December 31,
		2015			2014
	Land	$	5,773		$	5,773
	Buildings and improvements		170,128			154,374
	Equipment		136,351			122,184
	Office furniture and equipment		14,352			12,623
	Construction-in-progress		10,494			9,404
	Property, plant and equipment, gross	$	337,098		$	304,358
	Less: Accumulated depreciation		(121,507	)		(116,189	)
	Property, plant and equipment, net	$	215,591		$	188,169
	In connection with the Transaction, the Company acquired $27.5 million in property, plant and equipment.

Note_8_Business_Acquisitions

Note 8 - Business Acquisitions	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	8. BUSINESS ACQUISITIONS
	On March 9, 2015, the Company completed its previously announced acquisition of all of the outstanding shares of common stock of Tower and Lineage, pursuant to the Stock Purchase Agreement dated as of October 8, 2014, by and among the Company, Tower, Lineage, Roundtable Healthcare Partners II, L.P., Roundtable Healthcare Investors II, L.P., and the other parties thereto, including holders of certain options and warrants to acquire the common stock of Tower or Lineage. In connection with the Transaction, options and warrants of Tower and Lineage were cancelled. The aggregate consideration for Tower and Lineage was approximately $700 million, which included the repayment of indebtedness of Tower and Lineage, and an additional amount for cash acquired and other working capital adjustments at closing of approximately $39 million, all of which are subject to post-closing adjustments. The Company financed the Transaction from cash on hand and the full amount of borrowings available under its new $435 million senior secured term loan pursuant to a credit agreement dated as of March 9, 2015, by and among the Company, the lenders party thereto from time to time and Barclays Bank plc, as administrative and collateral agent (the “Credit Agreement”). Pursuant to the Credit Agreement, the Company also entered into a new $50 million senior secured revolving credit facility, which was not drawn as of March 31, 2015. As a result of the Transaction, Tower and Lineage became wholly owned subsidiaries of the Company. The Company incurred acquisition-related costs related to the Transaction of approximately $9 million, of which approximately $6 million are included in selling, general and administrative expenses in the Company’s consolidated statement of operations for the three months ended March 31, 2015.
	The Transaction allows the Company to expand its commercialized generic and branded product portfolios; the Company also intends to utilize its sales and marketing organization to promote the marketed products acquired in the Transaction.
	Consideration
	The Company has accounted for the Transaction as a business combination under the acquisition method of accounting. The Company has preliminarily allocated the purchase price for the Transaction based upon the estimated fair value of net assets acquired and liabilities assumed at the date of acquisition. Accordingly, the preliminary purchase price allocation described below is subject to change. The Company expects to finalize the allocation of the purchase price upon receipt of final valuations for the intangible assets, final resolution of post-closing working capital adjustments and certain tax accounts that are based on the best estimates of management. The completion and filing of federal and state tax returns for the various purchased entities of the Transaction may result in adjustments to the carrying value of assets and liabilities. Any adjustments to the preliminary fair values will be made as soon as practicable but no later than one year from the March 9, 2015 acquisition date.
	Recognition and Measurement of Assets Acquired and Liabilities Assumed at Fair Value
	The following tables summarize the preliminary fair values of the tangible and identifiable intangible assets acquired and liabilities assumed in the Transaction at the acquisition date, net of cash acquired of approximately $41 million:
	(in $000’s)
	Accounts receivable(1)		$	55,451
	Inventory			31,021
	Income tax receivable and other prepaid expenses			11,704
	Deferred income taxes			37,716
	Property, plant and equipment			27,539
	Intangible assets			727,600
	Assets held for sale			4,000
	Goodwill			124,476
	Other non-current assets			6,861
	Total assets assumed			1,026,368
	Current liabilities			61,595
	Other non-current liabilities			6,413
	Deferred tax liability			261,177
	Total liabilities assumed			329,185
	Cash paid, net of cash acquired		$	697,183
		-1	The accounts receivable acquired in the Transaction had a fair value of approximately $55 million, including an allowance for doubtful accounts of approximately $9 million, which represents the Company’s best estimate on March 9, 2015 (the closing date of the Transaction) of the contractual cash flows not expected to be collected by the acquired companies in the Transaction.
	Intangible Assets
	The following table identifies the Company’s preliminary allocations of purchase price to intangible assets including the weighted average amortization period in total and by major intangible asset class:
	(in $000’s)					Weighted Average
			Estimated Fair			Estimated Useful
			Value			Life (in years)
	Currently marketed products		$	380,900		13
	Royalties and contract manufacturing relationships			80,800		12
	In-process research and development			265,900		n/a
	Total intangible assets		$	727,600		12
	The estimated fair value of the in-process research and development and identifiable intangible assets was determined using the “income approach,” which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. Some of the more significant assumptions inherent in the development of those asset valuations include the estimated net cash flows for each year for each asset or product (including net revenues, cost of sales, research and development costs, selling and marketing costs and working capital/asset contributory asset charges), the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream as well as other factors. The discount rates used to arrive at the present value at the acquisition date of currently marketed products was 15% and for in-process research and development was 16% to reflect the internal rate of return and incremental commercial uncertainty in the cash flow projections. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results.
	Goodwill
	The Company recorded approximately $124 million of goodwill in connection with the Transaction, all of which will not be tax-deductible. Approximately $38 million of this goodwill was assigned to the Impax Specialty Pharma segment and approximately $86 million was assigned to the Impax Generics segment. Factors that contributed to the Company’s preliminary recognition of goodwill include the Company’s intent to expand its generic and branded pharmaceuticals product portfolios and to acquire certain benefits from the Tower and Lineage product pipelines through the Transaction in addition to the anticipated synergies that the Company expects to generate from the acquisition.
	Revenues and Earnings from Tower and Lineage for the Three Months Ended March 31, 2015
	Included in the Company’s consolidated statement of operations for the three months ended March 31, 2015 were revenues of approximately $14 million and loss before income taxes of approximately $5 million, representing the results of operations of Tower and Lineage and their subsidiaries.
	Unaudited Pro Forma Results of Operations
	The unaudited pro forma combined results of operations for the three months ended March 31, 2015 and 2014 (assuming the closing of the acquisition of Tower and Lineage occurred on January 1, 2014) are as follows:
			Three Months Ended
			March 31,
			2015				2014
	(in $000’s)
	Total revenues		$	175,533			$	174,067
	Net loss			(6,595	)			(12,679	)
	The pro forma results have been prepared for comparative purposes only and are not necessarily indicative of the actual results of operations had the closing of the Transaction taken place on January 1, 2014. Furthermore, the pro forma results do not purport to project the future results of operations of the Company.
	The unaudited pro forma information reflects primarily the following adjustments:
		•	Adjustments to amortization expense related to identifiable intangible assets acquired;
		•	Adjustments to depreciation expense related to property, plant and equipment acquired;
		•	Adjustments to interest expense to reflect the long-term debt held by Tower and Lineage paid out and eliminated at the closing and the Company’s new Senior Secured Credit Facilities (described in detail in “Note 12. – Debt” below);
		•	Adjustments to cost of revenues related to the fair value adjustments in inventory sold including elimination of approximately $1 million for the three months ended March 31, 2015 and additional costs of approximately $4 million for the corresponding comparative period;
		•	Adjustments to selling, general and administrative expense related to severance and retention costs of approximately $3 million incurred as part of the Transaction.  These costs were eliminated in the pro forma results for the three months ended March 31, 2015 and included in the corresponding comparative period;
		•	Adjustments to selling, general and administrative expense related to transaction costs directly attributable to the Transaction include the elimination of $12 million of charges in the three month period ended March 31, 2015 which have been included in the three month period ended March 31, 2014 and $4 million of charges incurred in the second half of fiscal year 2014 which have been included in the three month period ended March 31, 2015; and
		•	Adjustments to reflect the elimination of approximately $2.3 million in commitment fees related to its $435 million term loan that were incurred during the three months ended March 31, 2015 and inclusion in the corresponding comparative period.
	All of the above adjustments were adjusted for the applicable tax impact.

Note_9_Goodwill_and_Intangible

Note 9 - Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	9. GOODWILL AND INTANGIBLE ASSETS
	Goodwill was $152,050,000 at March 31, 2015 and $27,574,000 at December 31, 2014, respectively. In connection with the Transaction, the Company recorded approximately $124.5 million of goodwill. As of March 31, 2015, the Company attributes $114 million of goodwill to Impax Generics and $38 million to Impax Specialty Pharma. Goodwill is tested at least annually for impairment or whenever events or changes in circumstances have occurred which could have a material adverse effect on the estimated fair value of the reporting unit, and thus indicate a potential impairment of the goodwill carrying value. The Company concluded the carrying value of goodwill was not impaired as of December 31, 2014.
	Intangible assets consisted of the following:
	(in $000’s)		Initial		Accumulated			Impairment			Carrying
	31-Mar-15		Cost		Amortization						Value
	Amortized intangible assets:
	Tower currently marketed products		$	380,900	$	(2,804	)	$	---		$	378,096
	Tower in-process research and development			265,900		---			---			265,900
	Tower royalties and CMO relationships			80,800		---			---			80,800
	Zomig® product rights			41,783		(32,291	)		---			9,492
	Tolmar product rights			33,450		(11,351	)		(16,032	)		6,067
	Perrigo product rights			1,000		(334	)		---			666
	Ursodiol product rights			3,000		(496	)		---			2,504
	Other product rights			7,250		---			(750	)		6,500
	Total intangible assets		$	814,083	$	(47,276	)	$	(16,782	)	$	750,025
	(in $000’s)		Initial		Accumulated			Impairment			Carrying
	31-Dec-14		Cost		Amortization						Value
	Amortized intangible assets:
	Zomig® product rights		$	41,783	$	(31,561	)	$	---		$	10,222
	Tolmar product rights			33,450		(10,801	)		(16,032	)		6,617
	Perrigo product rights			1,000		(297	)		---			703
	Ursodiol product rights			3,000		(331	)		---			2,669
	Other product rights			7,250		---			(750	)		6,500
	Total intangible assets		$	86,483	$	(42,990	)	$	(16,782	)	$	26,711
	In connection with the Transaction, the Company acquired approximately $728 million of intangible assets (“Tower products”). See “Note 8 - Business Acquisitions.”
	The Zomig® product rights under the Distribution, License, Development and Supply Agreement (“AZ Agreement”) with AstraZeneca UK Limited (“AstraZeneca”) were amortized on a straight-line basis over a period of 14 months starting in April 2012 and ending upon the expiration of the underlying patent for the tablet and over a period of 11 months starting in July 2012 and ending upon the expiration of the underlying patent for the orally disintegrating tablet. The Zomig® product rights under the AZ Agreement are also being amortized over a period of 72 months starting in July 2012 for the nasal spray. In June 2012, the Company entered into a Development, Supply and Distribution Agreement (the “Tolmar Agreement”) with TOLMAR, Inc. (“Tolmar”). Under the terms of the Tolmar Agreement, Tolmar granted to the Company an exclusive license to commercialize up to 11 generic topical prescription drug products, including ten currently approved products and one product pending approval at the FDA, in the United States and its territories. Under the terms of the Tolmar Agreement, Tolmar is responsible for developing and manufacturing the products, and the Company is responsible for the marketing and sale of the products. During the three month period ended September 30, 2013, as a result of the most recent market share data obtained by the Company and the Company’s revised five year projections for the Tolmar product lines, the Company performed an intangible asset impairment test on the Tolmar products. Based on the results of the impairment analysis, the Company recorded a $13.2 million impairment charge to cost of revenues for Impax Generics in the three month period ended September 30, 2013. During the three month period ended March 31, 2014, as a result of a further decline in pricing, the Company revised its projections and performed an intangible asset impairment analysis. Based on the results of this analysis, the Company recorded a $2.9 million charge to cost of revenues for Impax Generics, which was 100% of the remaining net book value of this asset. The remaining carrying value of the Tolmar product rights are being amortized over the remaining estimated useful lives of the underlying products over a period ranging from five to 12 years, starting upon commencement of commercialization activities by the Company during the year ended December 31, 2012. Information concerning the AZ Agreement and the Tolmar Agreement can be found in “Note 13 - Alliance and Collaboration Agreements.” During the three month period ended June 30, 2014, the Company paid a $1.0 million milestone payment to Perrigo Company, plc (“Perrigo”) in conjunction with its launch of a generic version of Astepro® nasal spray pursuant to a development agreement between the Company and an affiliate of Perrigo. The milestone was capitalized as an intangible asset acquisition and will be amortized over the expected cash flows of the product. During the three month period ended September 30, 2014, the Company acquired from Actavis two generic products including one product marketed under an existing ANDA, the Ursodiol tablet, and one approved product that was not yet then marketed, the Lamotrigine orally disintegrating tablet. The entire purchase price was allocated to identifiable intangible assets and the Ursodiol intangible will be amortized over an eight year period. The Lamotrigine product was considered in-process research and development and will begin amortizing when commercialized. The Company received FDA approval of the Lamotrigine tablet in blister packaging in January 2015 and launched the product in early April 2015. Other product rights consist of ANDAs which have been filed with the FDA. During the three month period ended September 30, 2013, as a result of a decision by management to withdraw one of these ANDAs and no longer seek FDA approval, the Company recorded an intangible asset impairment charge of $0.8 million in research and development expense, representing the full carrying value of the ANDA. For the remaining ANDAs, the Company will either commence amortization upon FDA approval and commercialization over the estimated useful life of the product rights, or will expense the related costs immediately upon failure to obtain FDA approval. Amortization expense is included as a component of cost of revenues on the consolidated statement of operations and was $4,286,000 and $2,430,000 for the three month periods ended March 31, 2015 and 2014, respectively.
	The following schedule shows the expected amortization of the Tower, Zomig®, Tolmar, Perrigo and Ursodiol product rights as of March 31, 2015 for the next five years and thereafter:
	(in $000s)	Amortization
		Expense
	2015	$	38,887
	2016		35,986
	2017		32,723
	2018		37,922
	2019		35,845
	Thereafter		296,262
	Totals	$	477,625

Note_10_Accrued_Expenses_Commi

Note 10 - Accrued Expenses, Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Accrued Liabilities Disclosure [Abstract]
Accrued Liabilities Disclosure [Text Block]	10. ACCRUED EXPENSES, COMMITMENTS AND CONTINGENCIES
	The following table sets forth the Company’s accrued expenses:
	(in $000’s)	March 31,			December 31,
		2015			2014
	Payroll-related expenses	$	30,486		$	33,812
	Product returns		47,402			27,174
	Government rebates		30,470			18,272
	Legal and professional fees		13,484			9,497
	Income taxes payable		258			40
	Physician detailing sales force fees		2,545			2,336
	Litigation accrual		12,750			12,750
	Other		9,112			6,589
	Total accrued expenses	$	146,507		$	110,470
	Product Returns
	The Company maintains a return policy to allow customers to return product within specified guidelines. At the time of sale, the Company estimates a provision for product returns based upon historical experience for sales made through Impax Generics and Impax Specialty Pharma sales channels. Sales of product under the Private Label, Rx Partner and OTC Partner alliance and collaboration agreements are generally not subject to returns. A roll forward of the product returns reserve for the three month period ended March 31, 2015 and for the year ended December 31, 2014 is as follows:
	(in $000’s)	March 31,			December 31,
	Returns Reserve	2015			2014
	Beginning balance	$	27,174		$	28,089
	Acquired balances		19,030			--
	Provision related to sales recorded in the period		9,047			12,016
	Credits issued during the period		(7,849	)		(12,931	)
	Ending balance	$	47,402		$	27,174
	Litigation Accrual
	Included in accrued expenses is a $12,750,000 liability related to two consolidated securities class action settlements, as disclosed in “Note 18 - Legal and Regulatory Matters.” The settlement amounts will be paid for and covered by the Company's insurance policy; therefore, there is a corresponding $12,750,000 asset recorded in “Prepaid Expenses and Other Current Assets” on the consolidated balance sheet as of March 31, 2015 and December 31, 2014.
	Taiwan Facility Construction
	The Company has entered into several contracts relating to ongoing construction at its manufacturing facility located in Jhunan, Taiwan, R.O.C. As of March 31, 2015, the Company had remaining obligations under these contracts of approximately $495,000.
	Purchase Order Commitments
	As of March 31, 2015, and excluding the Taiwan Facility Construction, the Company had $72,007,000 of open purchase order commitments, primarily for raw materials. The terms of these purchase order commitments are generally less than one year in duration.

Note_11_Income_Taxes

Note 11 - Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	11. INCOME TAXES
	The Company calculates its interim income tax provision in accordance with FASB ASC Topics 270 and 740. At the end of each interim period, the Company makes an estimate of the annual United States domestic and foreign jurisdictions’ expected effective tax rates and applies these rates to its respective year-to-date taxable income or loss. The computation of the annual estimated effective tax rates at each interim period requires certain estimates and assumptions including, but not limited to, the expected operating income for the year, projections of the proportion of income (or loss) earned and taxed in the United States, and the various state and local tax jurisdictions, as well as tax jurisdictions outside the United States, along with permanent differences, and the likelihood of deferred tax asset utilization. The accounting estimates used to compute the provision for income taxes may change as new events occur, more experience is acquired or additional information is obtained. The computation of the annual estimated effective tax rate includes modifications, which were projected for the year, for share-based compensation and state research and development credits, among others. In addition, the effect of changes in enacted tax laws, rates, or tax status is recognized in the interim period in which the respective change occurs.
	During the three month period ended March 31, 2015, the Company recognized an aggregate consolidated tax benefit of $4,372,000 for U.S. domestic and foreign income taxes. In the three month period ended March 31, 2014, the Company recognized an aggregate consolidated tax provision of $2,205,000 for U.S. domestic and foreign income taxes. The decrease in the tax provision resulted from lower consolidated income before taxes in the three month period ended March 31, 2015, as compared to the same period in the prior year. The effective tax rate of 41% for the three month period ended March 31, 2015 was higher than the effective tax rate of 26% for the prior year period as a result of a change in the timing and mix of U.S. and foreign income, and a higher add back for non-deductible executive compensation limited by section 162(m) of the Internal Revenue Code compared to the prior year period. The Company is closely monitoring the events and circumstances that determine the need for a valuation allowance related to state research and development tax credit carryforwards and have determined that it would be premature to set up the valuation allowance at this time.

Note_12_Debt

Note 12 - Debt	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	12. DEBT
	Prior Credit Facility
	The Company was a party to a Credit Agreement, as amended, with Wells Fargo Bank, N.A., as a lender and as administrative agent (the “Prior Credit Facility”), which provided the Company with a revolving line of credit in the aggregate principal amount of up to $50.0 million. The Prior Credit Facility matured in accordance with the terms therein on February 11, 2015. The Company had not borrowed any amounts under the Prior Credit Facility.
	Senior Secured Credit Facilities
	In connection with the Transaction, the Company entered into a $50.0 million senior secured revolving credit facility and a $435.0 million senior secured term loan facility (collectively, the “Senior Secured Credit Facilities”), pursuant to a credit agreement, dated as of March 9, 2015, by and among the Company, the lenders party thereto from time to time and Barclays Bank PLC, as administrative and collateral agent.
	The net proceeds from the term loan under the Senior Secured Credit Facilities (the “Term Loan”) were used to finance in part the consideration paid in the Transaction, to pay off certain existing indebtedness of Tower and its subsidiaries in connection with the Transaction and to pay fees and expenses related to the Transaction and the associated financings. The Term Loan will mature on March 9, 2021 and the revolving commitments and revolving loans under the Senior Secured Credit Facilities (the “Revolver”) will mature on March 9, 2020. No borrowings were drawn from the Revolver for the funding of the Transaction.
	The Term Loan amortizes in equal quarterly installments in an amount equal to 1.25% of the original principal amount thereof, with the remaining balance due at final maturity. Interest is payable on the Senior Secured Credit Facilities at a rate equal to the LIBOR rate or the base rate, plus an applicable margin. The applicable margin on borrowings under the Revolver may be increased or reduced by 0.25% based on a step down based on the first lien net leverage ratio.
	Up to $10.0 million of the Revolver is available for issuances of letters of credit and any such issuance of letters of credit will reduce the amount available under the Revolver on a dollar-for-dollar basis. The Company is required to pay a commitment fee to the lenders on the average daily unused portion of the Revolver at an initial rate of 0.50% per annum. The commitment fee rate may be increased or reduced by 0.125% based on a step down based on the first lien net leverage ratio.
	The Senior Secured Credit Facilities are guaranteed by each of the Company’s current and future direct and indirect wholly owned material domestic subsidiaries other than (i) unrestricted subsidiaries, (ii) certain immaterial subsidiaries, (iii) foreign subsidiaries and domestic subsidiaries that are “controlled foreign corporations”, (iv) certain holding companies of foreign subsidiaries, (v) not-for-profit subsidiaries, captive insurance companies and certain special purpose vehicles, and (vi) any subsidiary that is prohibited by applicable law or contractual obligation from guaranteeing the Senior Secured Credit Facilities or which would require governmental approval to provide a guarantee (unless such approval has been received).
	The Senior Secured Credit Facilities are secured by a first priority security interest (subject to permitted liens and certain other exceptions), on substantially all of the Company’s and the Guarantors’ (as defined in the Credit Agreement) assets.
	The Company may repay all or any portion of the outstanding Term Loans at any time, and may reduce the unutilized portion of the Revolver in whole or in part without premium or penalty, subject to redeployment costs in the case of prepayment of LIBOR borrowings other than on the last day of the relevant interest period.
	Subject to certain exceptions and reinvestment rights, the Senior Secured Credit Facilities require that 100% of the net cash proceeds from certain asset sales and debt issuances and 75% (subject to step downs based on first lien net leverage ratio) from excess cash flow for each fiscal year of the Company (commencing with the fiscal year ending December 31, 2015) must be used to pay down outstanding borrowings under the Senior Secured Credit Facilities.
	The Senior Secured Credit Facilities contain certain negative covenants (subject to exceptions, materiality thresholds and baskets) including, without limitation, negative covenants that limit the Company’s and its restricted subsidiaries’ ability to incur additional debt, guarantee other obligations, grant liens on assets, make loans, acquisitions or other investments, dispose of assets, make optional payments or modify certain debt instruments, pay dividends or other payments on capital stock, engage in mergers or consolidations, enter into arrangements that restrict the Company’s and its restricted subsidiaries’ ability to pay dividends or grant liens, engage in transactions with affiliates, or change fiscal year. The Senior Secured Credit Facilities also include a financial maintenance covenant whereby the Company must not permit its trailing 12 month total net leverage ratio to exceed 3.5:1.0, tested at the end of each fiscal quarter commencing with the fiscal quarter ending June 30, 2015.
	The Senior Secured Credit Facilities contain events of default, including, without limitation (subject to customary grace periods and materiality thresholds), events of default upon (i) the failure to make payments under the Senior Secured Credit Facilities, (ii) violation of covenants, (iii) incorrectness of representations and warranties, (iv) cross-default and cross-acceleration to other material indebtedness in excess of $25.0 million, (v) bankruptcy events, (vi) material monetary judgments (to the extent not covered by insurance), (vii) certain matters arising under ERISA that could reasonably be expected to result in a material adverse effect, (viii) the actual or asserted invalidity of the documents governing the Senior Secured Credit Facilities, any material guarantees or the security interests (including priority thereof) required under the Senior Secured Credit Facilities and (ix) the occurrence of a change of control. Upon the occurrence of certain events of default, the obligations under the Senior Secured Credit Facilities may be accelerated and any remaining commitments thereunder (including the Revolver) may be terminated.
	In connection with the Senior Secured Credit Facilities, the Company incurred fees of $17.8 million which are reflected as a debt discount and are being amortized using the effective interest rate method over the term of the Senior Secured Credit Facilities. For the three month period ended March 31, 2015, approximately $0.2 million of amortization expense is included in interest expense on the Company's consolidated statement of operations. The Company also recorded $2.3 million in interest expenses related to a ticking fee paid to Barclays Bank PLC incurred prior to the funding of the Senior Secured Credit Facilities to lock in the financing terms beginning from the lenders’ commitment of the term loan to the actual allocation of the loan. For the three months ended March 31, 2015, accrued interest on the term loan was $1.5 million.
	In addition, during the three month period ended March 31, 2015, unused line fees incurred under the Senior Secured Credit Facilities were $11,000.
	Current and long-term debt are $18.7 million and $398.6 million, respectively, on the Company’s consolidated balance sheets as of March 31, 2015 and are presented net of unamortized debt discount of $3.0 million and $14.7 million, respectively.

Note_13_Alliance_and_Collabora

Note 13 - Alliance and Collaboration Agreements	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborative Arrangement Disclosure [Text Block]	13. ALLIANCE AND COLLABORATION AGREEMENTS
	The Company has entered into several alliance, collaboration, license and distribution agreements, and similar agreements with respect to certain of its products and services, with unrelated third-party pharmaceutical companies. The consolidated statement of operations includes revenue recognized under agreements the Company has entered into to develop marketing and/or distribution relationships with its partners to fully leverage its technology platform and revenue recognized under development agreements which generally obligate the Company to provide research and development services over multiple periods.
	The Company’s alliance and collaboration agreements often include milestones and provide for milestone payments upon achievement of these milestones. Generally, the milestone events contained in the Company’s alliance and collaboration agreements coincide with the progression of the Company’s products and technologies from pre-commercialization to commercialization.
	The Company groups pre-commercialization milestones in its alliance and collaboration agreements into clinical and regulatory categories, each of which may include the following types of events:
	Clinical Milestone Events:
		●	Designation of a development candidate. Following the designation of a development candidate, generally, IND-enabling animal studies for a new development candidate take 12 to 18 months to complete.
		●	Initiation of a Phase I clinical trial. Generally, Phase I clinical trials take one to two years to complete.
		●	Initiation or completion of a Phase II clinical trial. Generally, Phase II clinical trials take one to three years to complete.
		●	Initiation or completion of a Phase III clinical trial. Generally, Phase III clinical trials take two to four years to complete.
		●	Completion of a bioequivalence study. Generally, bioequivalence studies take three months to one year to complete.
	Regulatory Milestone Events:
		●	Filing or acceptance of regulatory applications for marketing approval such as a New Drug Application in the United States or Marketing Authorization Application in Europe. Generally, it takes six to 12 months to prepare and submit regulatory filings and approximately two months for a regulatory filing to be accepted for substantive review.
		●	Marketing approval in a major market, such as the United States or Europe. Generally it takes one to three years after an application is submitted to obtain approval from the applicable regulatory agency.
		●	Marketing approval in a major market, such as the United States or Europe for a new indication of an already-approved product. Generally it takes one to three years after an application for a new indication is submitted to obtain approval from the applicable regulatory agency.
	Commercialization milestones in the Company’s alliance and collaboration agreements may include the following types of events:
		●	First commercial sale in a particular market, such as in the United States or Europe.
		●	Product sales in excess of a pre-specified threshold, such as annual sales exceeding $100 million. The amount of time to achieve this type of milestone depends on several factors including but not limited to the dollar amount of the threshold, the pricing of the product and the pace at which customers begin using the product.
	License and Distribution Agreement with Shire
	In January 2006, the Company entered into a License and Distribution Agreement with an affiliate of Shire Laboratories, Inc., which was subsequently amended (“Prior Shire Agreement”), under which the Company received a non-exclusive license to market and sell an authorized generic of Shire’s Adderall XR® product (“AG Product”) subject to certain conditions, but in any event by no later than January 1, 2010. The Company commenced sales of the AG Product in October 2009. On February 7, 2013, the Company entered into an Amended and Restated License and Distribution Agreement with Shire (the “Amended and Restated Shire Agreement”), which amended and restated the Prior Shire Agreement. The Amended and Restated Shire Agreement was entered into by the parties in connection with the settlement of the Company’s litigation with Shire relating to Shire’s supply of the AG Product to the Company under the Prior Shire Agreement. Under the Amended and Restated Shire Agreement Shire was required to supply the AG Product and the Company was responsible for marketing and selling the AG Product subject to the terms and conditions thereof until the earlier of (i) the first commercial sale of the Company’s generic equivalent product to Adderall XR® and (ii) September 30, 2014 (the “Supply Term”), subject to certain continuing obligations of the parties upon expiration or early termination of the Supply Term, including Shire’s obligation to deliver AG Products still owed to the Company as of the end of the Supply Term. The Company is required to pay a profit share to Shire on sales of the AG Product of which the company owed a profit share payable to Shire of $5,834,000 and $4,447,000 on sales of the AG Product during the three month periods ended March 31, 2015 and 2014, respectively, with a corresponding charge included in the cost of revenues line on the consolidated statements of operations. Although the Supply Term expired on September 30, 2014, the Company is permitted to sell any AG Products in its inventory or owed to the Company by Shire under the Amended and Restated Shire Agreement until all such products are sold; the Company will pay a profit share to Shire on sales of such products.
	Development, Supply and Distribution Agreement with TOLMAR, Inc.
	In June 2012, the Company entered into the Tolmar Agreement with Tolmar. Under the terms of the Tolmar Agreement, Tolmar granted to the Company an exclusive license to commercialize up to 11 generic topical prescription drug products, including ten currently approved products and one product pending approval at the FDA, in the United States and its territories. Under the terms of the Tolmar Agreement, Tolmar is responsible for developing and manufacturing the products, and the Company is responsible for marketing and sale of the products. The Company is required to pay a profit share to Tolmar on sales of each product commercialized pursuant to the terms of the Tolmar Agreement. The Company paid Tolmar a $21,000,000 upfront payment upon signing of the agreement and a $1,000,000 milestone payment in the year ended December 31, 2012. During the fourth quarter of 2013, the Company made a $12,000,000 payment to Tolmar upon Tolmar’s achievement of a regulatory milestone event in accordance with the terms of the agreement. The upfront payment for the Tolmar product rights has been allocated to the underlying topical products based upon the relative fair value of each product and is being amortized over the remaining estimated useful life of each underlying product, ranging from five to 12 years, starting upon commencement of commercialization activities by the Company during the second half of 2012. The amortization of the Tolmar product rights has been included as a component of cost of revenues on the consolidated statement of operations. The Company initially allocated $1,550,000 of the upfront payment to two products which are still in development and recorded such amount as in-process research and development expense in its results of operations for the year ended December 31, 2012. The Company similarly recorded the $1,000,000 milestone paid in the year ended December 31, 2012 as a research and development expense. The Company is required to pay a profit share to Tolmar on sales of the products, of which the Company owed a profit share payable to Tolmar of $7,540,000 and $2,961,436 on sales of the products during the three month periods ended March 31, 2015 and 2014, respectively, with a corresponding charge included in the cost of revenues line on the consolidated statements of operations. Under the Tolmar Agreement, the Company has the potential to pay up to an aggregate of $10,000,000 in additional contingent milestone payments if certain commercialization events occur.
	Contingent milestone payments will be initially recognized in the period the triggering event occurs. Milestone payments which are contingent upon commercialization events will be accounted for as an additional cost of acquiring the product license rights. Milestone payments that are contingent upon regulatory approval events will be capitalized and amortized over the remaining estimated useful life of the approved product. During the fourth quarter of 2014, the Company paid a $2.0 million milestone related to the Diclofenac Sodium Gel 3% or Solaraze product to Tolmar pursuant to the Tolmar Agreement.
	The Company entered into a Loan and Security Agreement with Tolmar in March 2012 (the “Tolmar Loan Agreement”), under which the Company has agreed to lend to Tolmar one or more loans through December 31, 2014, in an aggregate amount not to exceed $15,000,000. As of March 31, 2015, Tolmar has borrowed the full amount of $15,000,000 under the Tolmar Loan Agreement. The outstanding principal amount of, including any accrued and unpaid interest on, the loans under the Tolmar Loan Agreement are payable by Tolmar beginning from March 31, 2017 through March 31, 2020 or the maturity date, in accordance with the terms therein. Tolmar may prepay all or any portion of the outstanding balance of the loans prior to the maturity date without penalty or premium.
	Strategic Alliance Agreement with Teva
	The Company entered into a Strategic Alliance Agreement with Teva Pharmaceuticals Curacao N.V., a subsidiary of Teva Pharmaceuticals Industries Limited, in June 2001 (“Teva Agreement”). The Teva Agreement commits the Company to develop and manufacture, and Teva to distribute, a specified number of controlled release generic pharmaceutical products (“generic products”), each for a 10-year period.
	The Company identified the following deliverables under the Teva Agreement: (i) the manufacture and delivery of generic products; (ii) the provision of research and development activities (including regulatory services) related to each product; and (iii) market exclusivity associated with the products. In July 2010, the Teva Agreement was amended to terminate the provisions of the Teva Agreement with respect to the Omeprazole (generic to Prilosec®) 10mg, 20mg and 40mg products. Additionally, in exchange for the return of product rights, the Company agreed to pay to Teva a profit share on future sales of the fexofenadine HCI/pseudoephedrine (generic to Allegra-D®) product, if any, but in no event will such profit share payments exceed an aggregate amount of $3,000,000.
	As of May 1, 2015, the Company was supplying Teva with Ditropan XL® 5,10 and 15 mg extended release tablets as the other products under the Teva Agreement have either been returned to the Company, are being manufactured by Teva at its election, were voluntarily withdrawn from the market or the Company’s obligations to supply such product had expired or were terminated in accordance with the agreement.
	OTC Partners Alliance Agreement
	In June 2002, the Company entered into a Development, License and Supply Agreement with Pfizer, Inc., formerly Wyeth LLC (“Pfizer”), for a term of approximately 15 years, relating to the Company’s Loratadine and Pseudoephedrine Sulfate 5 mg/120 mg 12-hour Extended Release Tablets and Loratadine and Pseudoephedrine Sulfate 10 mg/240 mg 24-hour Extended Release Tablets for the OTC market. The Company previously developed the products, and is currently only responsible for manufacturing the products, and Pfizer is responsible for marketing and sale. The agreement included payments to the Company upon achievement of development milestones, as well as royalties paid to the Company by Pfizer on its sales of the product. Pfizer launched this product in May 2003 as Alavert® D-12 Hour. In February 2005, the agreement was partially cancelled with respect to the 24-hour Extended Release Product due to lower than planned sales volume. In December 2011, Pfizer and the Company entered into an agreement with L. Perrigo Company (“Perrigo”) whereby the parties agreed that the Company would supply the Company’s Loratadine and Pseudoephedrine Sulfate 5 mg/120 mg 12-hour Extended Release Tablets to Perrigo in the United States and its territories. The agreements with Pfizer and Perrigo are no longer a core area of the Company’s business, and the over-the-counter pharmaceutical products the Company sells to Pfizer and Perrigo under the agreements are older products which are only sold to Pfizer and to Perrigo. As noted above, the Company is currently only required to manufacture the products under its agreements with Pfizer and Perrigo. The Company recognizes profit share revenue in the period earned.
	Joint Development Agreement with Valeant Pharmaceuticals International, Inc.
	In November 2008, the Company and Valeant Pharmaceuticals International, Inc., formerly Medicis Pharmaceutical Corporation (“Valeant”), entered into a Joint Development Agreement and a License and Settlement Agreement (“Joint Development Agreement”).The Joint Development Agreement provides for the Company and Valeant to collaborate in the development of a total of five dermatology products, including four of the Company’s generic products and one branded advanced form of Valeant’s SOLODYN® product. Under the provisions of the Joint Development Agreement the Company received a $40,000,000 upfront payment, paid by Valeant in December 2008. The Company has also received an aggregate of $15,000,000 in milestone payments composed of two $5,000,000 milestone payments, paid by Valeant in March 2009 and September 2009, a $2,000,000 milestone payment paid by Valeant in December 2009, and a $3,000,000 milestone payment paid by Valeant in March 2011. The Company has the potential to receive up to an additional $8,000,000 of contingent regulatory milestone payments each of which the Company believes to be substantive, as well as the potential to receive royalty payments from sales, if any, by Valeant of its advanced form SOLODYN® brand product. Finally, to the extent the Company commercializes any of its four generic dermatology products covered by the Joint Development Agreement, the Company will pay to Valeant a gross profit share on sales of such products. The Company began selling one of the four dermatology products during the year ended December 31, 2011. As of December 31, 2014, the full amount of deferred revenue under the Joint Development Agreement was recognized.
	Distribution, License, Development and Supply Agreement with AstraZeneca UK Limited
	In January 2012, the Company entered into the AZ Agreement with AstraZeneca. Under the terms of the AZ Agreement, AstraZeneca granted to the Company an exclusive license to commercialize the tablet, orally disintegrating tablet and nasal spray formulations of Zomig® (zolmitriptan) products for the treatment of migraine headaches in the United States and in certain United States territories, except during an initial transition period when AstraZeneca fulfilled all orders of Zomig® products on the Company’s behalf and AstraZeneca paid to the Company the gross profit on such Zomig® products. The Company is obligated to fulfill certain minimum requirements with respect to the promotion of currently approved Zomig® products as well as other dosage strengths of such products approved by the FDA in the future. The Company may, but has no obligation to, develop and commercialize additional products containing zolmitriptan and additional indications for Zomig®, subject to certain restrictions as set forth in the AZ Agreement. The Company will be responsible for conducting clinical studies and preparing regulatory filings related to the development of any such additional products and would bear all related costs. During the term of the AZ Agreement, AstraZeneca will continue to be the holder of the NDA for existing Zomig® products, as well as any future dosage strengths thereof approved by the FDA, and will be responsible for certain regulatory and quality-related activities for such Zomig® products. AstraZeneca will manufacture and supply Zomig® products to the Company and the Company will purchase its requirements of Zomig® products from AstraZeneca until a date determined in the AZ Agreement. Thereafter, AstraZeneca may terminate its supply obligations upon certain advance notice to the Company, in which case the Company would have the right to manufacture or have manufactured its own requirements for the applicable Zomig® product.
	Under the terms of the AZ Agreement, AstraZeneca was required to make payments to the Company representing 100% of the gross profit on sales of AstraZeneca-labeled Zomig® products during the specified transition period. The Company received transition payments from AstraZeneca aggregating $43,564,000 during 2012. The Company accounted for these payments as a reduction of the related receivable that was recorded in the initial purchase price allocation. The Company allocated $45,096,000 to an intangible asset, and the remaining $41,340,000 to prepaid royalty expense related to sales of Impax-labeled Zomig® products during 2012, with such royalty expense included in cost of revenues on the consolidated statement of operations. Beginning in January 2013, the Company was obligated to pay AstraZeneca tiered royalties on net sales of branded Zomig® products, depending on brand exclusivity and subject to customary reductions and other terms and conditions set forth in the AZ Agreement. The Company is also obligated to pay AstraZeneca royalties after a certain specified date based on gross profit from sales of authorized generic versions of the Zomig® products subject to certain terms and conditions set forth in the AZ Agreement. In May 2013, the Company’s exclusivity period for branded Zomig® tablets and orally disintegrating tablets expired and the Company launched authorized generic versions of those products in the United States. The Company owed a royalty payable to AstraZeneca of $4,025,000 and $2,615,000 during the three month periods ended March 31, 2015 and 2014, respectively, with a corresponding charge included in the cost of revenues line on the consolidated statements of operations.
	Development and Co-Promotion Agreement with Endo Pharmaceuticals, Inc.
	In June 2010, the Company and Endo Pharmaceuticals, Inc. ("Endo") entered into a Development and Co-Promotion Agreement (“Endo Agreement”) under which the Company and Endo have agreed to collaborate in the development and commercialization of a next-generation advanced form of the Company’s lead brand product candidate ("Endo Agreement Product"). Under the provisions of the Endo Agreement, in June 2010, Endo paid to the Company a $10,000,000 upfront payment. The Company has the potential to receive up to an additional $30,000,000 of contingent milestone payments, which includes $15,000,000 contingent upon the achievement of clinical events, $5,000,000 contingent upon the achievement of regulatory events, and $10,000,000 contingent upon the achievement of commercialization events. The Company believes all milestones under the Endo Agreement are substantive. Upon commercialization of the Endo Agreement Product in the United States, Endo will have the right to co-promote such product to non-neurologists, which will require the Company to pay Endo a co-promotion service fee of up to 100% of the gross profits attributable to prescriptions for the Endo Agreement Product which are written by the non-neurologists.
	The Company is recognizing the $10,000,000 upfront payment as revenue on a straight-line basis over a period of 112 months, which is the estimated expected period of performance of research and development activities under the Endo Agreement, commencing with the June 2010 effective date of the Endo Agreement and ending in September 2019, the estimated date of FDA approval of the Company's NDA. The FDA approval of the Endo Agreement Product NDA represents the end of the Company’s expected period of performance, as the Company will have no further contractual obligation to perform research and development activities under the Endo Agreement, and therefore the earnings process will be completed. Deferred revenue is recorded as a liability captioned “Deferred revenue” on the consolidated balance sheet and deferred revenue under the Endo Agreement was $4,083,000 as of March 31, 2015. Revenue recognized under the Endo Agreement is reported in the line item “Other Revenues” in “Note 19 - Supplementary Financial Information.” The Company determined the straight-line method aligns revenue recognition with performance as the level of research and development activities performed under the Endo Agreement are expected to be performed on a ratable basis over the Company’s estimated expected period of performance. Upon FDA approval of the Company’s Endo Agreement Product NDA, the Company will have the right (but not the obligation) to begin manufacture and sale of such product. The Company will sell its manufactured branded product to customers in the ordinary course of business through Impax Specialty Pharma. The Company will account for any sale of the product covered by the Endo Agreement as current period revenue. The co-promotion service fee paid to Endo, as described above, if any, will be accounted for as a current period selling expense as incurred.
	The Company and Endo also entered into a Settlement and License Agreement in June 2010 (the “Endo Settlement Agreement”) pursuant to which Endo agreed to make a payment to the Company should Prescription Sales of Opana® ER (as defined in the Endo Settlement Agreement) fall below a predetermined contractual threshold in the quarter immediately prior to the Company launching a generic version of Opana® ER.
	Agreement with DURECT Corporation
	During the three month period ended March 31, 2014, the Company entered into an agreement with DURECT Corporation (“Durect”) granting the Company the exclusive worldwide rights to develop and commercialize DURECT’s investigational transdermal bupivacaine patch for the treatment of pain associated with post-herpetic neuralgia (PHN), referred to by the Company as IPX239. The Company paid Durect a $2,000,000 up-front payment upon signing of the agreement which was recognized immediately as research and development expense. The Company has the potential to pay up to $61,000,000 in additional contingent milestone payments upon the achievement of predefined development and commercialization milestones. If IPX239 is commercialized, Durect would also receive a tiered royalty on product sales.
	Product Acquisition Agreement with Teva Pharmaceuticals USA, Inc.
	In August 2013, the Company, through its Amedra Pharmaceuticals subsidiary, entered into a product acquisition agreement (the “Teva Product Acquisition Agreement”) with Teva Pharmaceuticals USA, Inc. (“Teva”) pursuant to which the Company acquired the assets (including the ANDA and other regulatory materials) and related liabilities related to Teva’s mebendazole tablet product in all dosage forms (the “Mebendazole Tablet”). The Company has the potential to pay up to $3,500,000 in additional contingent milestone payments upon the achievement of predefined regulatory and commercialization milestones. The Company is also obligated to pay Teva a royalty payment based on net sales of the Mebendazole Tablet, including a specified annual minimum royalty payment, subject to customary reductions and the other terms and conditions set forth in the Teva Product Acquisition Agreement.
	Master Development Agreement with RiconPharma LLC
	In June 2013, the Company, through its Amedra Pharmaceuticals subsidiary, entered into a development agreement (the “Albendazole Agreement”) with RiconPharma LLC (“RiconPharma”). Under the terms of the Albendazole Agreement, RiconPharma is responsible for the development of Albendazole 400 mg tablets (the “Albendazole Tablet”) and the Company is responsible for the marketing and sale of the Albendazole Tablets. The Company made an incentive cash payment of $225,000 to RiconPharma during the fourth quarter of 2014 upon the achievement of a specified development milestone. The Company is also obligated to pay RiconPharma tiered royalty payments based on net sales of the Albendazole Tablet, subject to customary reductions and the other terms and conditions set forth in the agreement.
	Master Development Agreement with RiconPharma LLC
	In May 2011, the Company, through its CorePharma subsidiary, entered into an amended and restated master development Agreement with RiconPharma LLC (the “Amended and Restated Development Agreement”) which amended and restated the development agreement between the parties dated September 21, 2009, as amended. Under the Amended and Restated Development Agreement, RiconPharma is responsible for exclusively developing and manufacturing, on a non-exclusive basis, for the Company and the Company is responsible for commercializing Griseofulvin Ultra-microcrystalline 125 mg and 250 mg tablets. The Company has the potential to pay up to $500,000 in contingent milestone payments upon the achievement of certain specified commercialization milestones for each product, as specified in the agreement. The Company is also obligated to pay RiconPharma tiered profit share payments based on net sales of the products, subject to customary reductions and the other terms and conditions set forth in the agreement.
	Product Agreement with Pfizer Inc.
	In January 2008, the Company, through its CorePharma subsidiary, entered into a Product Agreement (the “Pfizer Product Agreement”) with Pfizer, formerly King Pharmaceuticals, Inc. (“Pfizer”), under which the Company received the non-exclusive right to manufacture, market and sell an authorized generic of Pfizer’s Skelaxin® 800 mg product (the “Pfizer AG Product”). The Company is obligated to pay Pfizer a distribution fee based on net sales of the Pfizer AG Product, subject to terms and conditions set forth in the Pfizer Product Agreement. Pursuant to a Manufacturing and Supply Agreement dated as of August 29, 2013 with Pfizer, the Company is also obligated to manufacture and supply the branded Skelaxin® 800 mg product to Pfizer in accordance with the terms of such agreement.
	License, Supply and Distribution Agreement with Micro Labs Limited
	In June 2012, the Company, through its CorePharma subsidiary, entered into a License, Supply and Distribution Agreement (“Micro Labs Agreement”) with Micro Labs Limited (“Micro Labs”), under which the Company received an exclusive license to commercialize and distribute a generic equivalent of Arthrotec® tablets (the “Diclofenac Sodium and Misoprostol Product”) in the U.S. and its possessions and territories, and Micro Labs agreed to exclusively supply such the Diclofenac Sodium and Misoprostol Product to the Company for the U.S. and its possessions and territories, in each case subject to the terms and conditions in the agreement. The Company has the potential to pay up to $750,000 in contingent milestone payments upon the achievement of predefined development milestones. The Company is also obligated to pay Micro Labs a profit share based on net sales of the Diclofenac Sodium and Misoprostol Product, subject to the terms and conditions set forth in the agreement.

Note_14_Sharebased_Compensatio

Note 14 - Share-based Compensation	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	14. SHARE-BASED COMPENSATION
	The Company recognizes the grant date fair value of each stock option and restricted stock award over its vesting period. Stock options and restricted stock awards are granted under the Company’s Second Amended and Restated 2002 Equity Incentive Plan (“2002 Plan”) and generally vest over a three or four year period and have a term of ten years. Total share-based compensation expense recognized in the consolidated statement of operations during the three month periods ended March 31, 2015 and 2014 were as follows:
		Three Months Ended
		March 31,
	(in $000’s)	2015			2014
	Manufacturing expenses	$	1,046		$	896
	Research and development		1,365			1,402
	Selling, general and administrative		4,077			2,088
	Total	$	6,488		$	4,386
	The following table summarizes stock option activity during the three month period ended March 31, 2015:
		Number of			Weighted
		Shares			Average
		Under			Exercise
		Option			Price
					per Share
	Outstanding at December 31, 2014		3,042,180		$	14.78
	Options granted		335,750		$	40.66
	Options exercised		(216,008	)	$	12.04
	Options forfeited		--		$	--
	Outstanding at March 31, 2015		3,161,922		$	17.72
	Options exercisable at March 31, 2015		2,460,957		$	12.91
	The Company estimated the fair value of each stock option award on the grant date using the Black-Scholes option pricing model. Expected volatility is based solely on historical volatility of the Company’s common stock. The expected term calculation is based on the “simplified” method described in SAB No. 107, Share-Based Payment and SAB No. 110, Share-Based Payment, as the result of the simplified method provides a reasonable estimate in comparison to the Company’s actual experience. The risk-free interest rate is based on the U.S. Treasury yield at the date of grant for an instrument with a maturity that is commensurate with the expected term of the stock options. The dividend yield of zero is based on the fact that the Company has never paid cash dividends on its common stock, and has no present intention to pay cash dividends.
	A summary of the Company’s non-vested restricted stock awards activity during the three month period ended March 31, 2015 is presented below:
	Restricted Stock Awards	Number of			Weighted
		Restricted			Average
		Stock Awards			Grant Date
					Fair Value
	Non-vested at December 31, 2014		2,327,176		$	23.61
	Granted		210,660		$	39.09
	Vested		(26,066	)	$	21.89
	Forfeited		(29,681	)	$	24.4
	Non-vested at March 31, 2015		2,482,089		$	24.93
	The Company grants restricted stock awards to certain eligible employees and directors as a component of its long-term incentive compensation program. The restricted stock award grants are made in accordance with the Company’s 2002 Plan, and typically specify that the shares of common stock underlying the restricted stock awards are not issued until they vest. The restricted stock awards generally vest ratably over a three or four year period from the date of grant.
	As of March 31, 2015, the Company had total unrecognized share-based compensation expense, net of estimated forfeitures, of $56,450,000 related to all of its share-based awards, which will be recognized over a weighted-average period of 2.09 years. As of March 31, 2015, the Company estimated 2,799,227 stock options and 2,197,376 shares of restricted stock awards granted to employees which were vested or expected to vest. The intrinsic value of stock options exercised during the three month periods ended March 31, 2015 and 2014 was $4,221,000 and $3,789,000, respectively. The total fair value of restricted stock awards which vested during the three month periods ended March 31, 2015 and 2014 was $571,000 and $621,000, respectively. As of March 31, 2015, the Company had 2,190,892 shares of common stock available for issuance of stock options, restricted stock awards, and/or stock appreciation rights.

Note_15_Stockholders_Equity

Note 15 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	15. STOCKHOLDERS’ EQUITY
	Preferred Stock
	Pursuant to its certificate of incorporation, the Company is authorized to issue 2,000,000 shares, $0.01 par value per share, “blank check” preferred stock, which enables the Board of Directors, from time to time, to create one or more new series of preferred stock. Each series of preferred stock issued can have the rights, preferences, privileges and restrictions designated by the Board of Directors. The issuance of any new series of preferred stock could affect, among other things, the dividend, voting, and liquidation rights of the Company’s common stock. During the three month periods ended March 31, 2015 and 2014, the Company did not issue any preferred stock.
	Common Stock
	The Company’s certificate of incorporation, as amended, authorizes the Company to issue 90,000,000 shares of common stock with $0.01 par value.

Note_16_Earnings_Per_Share

Note 16 - Earnings Per Share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	16. EARNINGS PER SHARE
	The Company's earnings per share (EPS) includes basic net income per share, computed by dividing net (loss) income (as presented on the consolidated statement of operations), by the weighted average number of shares of common stock outstanding for the period, along with diluted net (loss) income per share, computed by dividing net income by the weighted average number of shares of common stock adjusted for the dilutive effect of common stock equivalents outstanding during the period. A reconciliation of basic and diluted net (loss)  income per share of common stock for the three month periods ended March 31, 2015 and 2014 were as follows:
		Three Months Ended
		March 31,
	(in $000’s except share and per share amounts)	2015			2014
	Numerator:
	Net (loss) income	$	(6,333	)	$	6,425
	Denominator:
	Weighted average common shares outstanding		68,967,875			67,702,296
	Effect of dilutive stock options and restricted stock awards		--			2,236,576
	Diluted weighted average common shares outstanding		68,967,875			69,938,872
	Basic net (loss) income per share	$	(0.09	)	$	0.09
	Diluted net (loss) income per share	$	(0.09	)	$	0.09
	For the three month period ended March 31, 2015, the Company had a net loss. Only the weighted average of common shares outstanding has been used to calculate both basic earnings per share and diluted earnings per share for the three month period ended March 31, 2015, as inclusion of the potential common shares would have been anti-dilutive. For the three month period ended March 31, 2014, the Company excluded 331,500 of shares issuable upon the exercise of stock options and unvested restricted stock awards from the computation of diluted net income per common share as the effect of these options and unvested restricted stock awards would have been anti-dilutive. Quarterly computations of net income per share amounts are made independently for each quarterly reporting period, and the sum of the per share amounts for the quarterly reporting periods may not equal the per share amounts for the year-to-date reporting period.

Note_17_Segment_Information

Note 17 - Segment Information	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	17. SEGMENT INFORMATION
	The Company has two reportable segments, Impax Generics and Impax Specialty Pharma. Impax Generics develops, manufactures, sells, and distributes generic pharmaceutical products, primarily through the following sales channels: the Impax Generics sales channel for sales of generic prescription products directly to wholesalers, large retail drug chains, and others; the Private Label Product sales channel for generic over-the-counter and prescription products sold to unrelated third-party customers who, in turn, sell the products under their own label; the Rx Partner sales channel for generic prescription products sold through unrelated third-party pharmaceutical entities under their own label pursuant to alliance agreements; and the OTC Partner sales channel for over-the-counter products sold through unrelated third-party pharmaceutical entities under their own labels pursuant to alliance and supply agreements. Revenues from the “Impax Generics” sales channel and the “Private Label” sales channel are reported under the caption “Impax Generics sales, net” in “Note 19 – Supplementary Financial Information.” The Company also generates revenue in Impax Generics from research and development services provided under a joint development agreement with another unrelated third-party pharmaceutical company, and reports such revenue under the caption “Other Revenues” revenue in “Note 19 – Supplementary Financial Information.” Revenues from the “OTC Partner” sales channel are also reported under the caption “Other Revenues” in “Note 19 – Supplementary Financial Information.”
	Impax Specialty Pharma is engaged in the development of proprietary brand pharmaceutical products that the Company believes represent improvements to already-approved pharmaceutical products addressing central nervous system (“CNS”) disorders and other select specialty segments. Impax Specialty Pharma currently has one internally developed branded pharmaceutical product, RYTARY® (IPX066), an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and/or manganese intoxication, which was approved by the FDA on January 7, 2015. The Company has also filed the required documents for a Market Authorization Application to the European Medicines Agency (EMA) for IPX066 on November 5, 2014 and the filing was accepted by the EMA on November 26, 2014. The Company is currently also seeking to identify a licensing partner for the development and commercialization of IPX066 in countries outside of the U.S. Impax Specialty Pharma is also engaged in the sale and distribution of four other branded products including Zomig® (zolmitriptan) products, indicated for the treatment of migraine headaches, under the terms of a Distribution, License, Development and Supply Agreement (“AZ Agreement”) with AstraZeneca UK Limited (“AstraZeneca”) in the United States and in certain U.S. territories, and Albenza®, indicated for the treatment of tapeworm infections. Revenues from Impax-labeled branded products are reported under the caption “Impax Specialty Pharma sales, net” in “Note 19 – Supplementary Financial Information.” Finally, the Company generates revenue in Impax Specialty Pharma from research and development services provided under a development and license agreement with another unrelated third-party pharmaceutical company, and reports such revenue under the caption “Other Revenues” in “Note 19 – Supplementary Financial Information.” Impax Specialty Pharma also has a number of product candidates that are in varying stages of development. Revenues from Impax-labeled branded products are reported under the caption “Impax Specialty Pharma sales, net” in “Note 19 – Supplementary Financial Information.” Finally, the Company generates revenue in Impax Specialty Pharma from research and development services provided under a development and license agreement with another unrelated third-party pharmaceutical company, and reports such revenue under the caption “Other Revenues” in “Note 19 – Supplementary Financial Information.” Impax Specialty Pharma also has a number of product candidates that are in varying stages of development.
	The Company’s chief operating decision maker evaluates the financial performance of the Company’s segments based upon segment income (loss) before income taxes. Items below income (loss) from operations are not reported by segment, since they are excluded from the measure of segment profitability reviewed by the Company’s chief operating decision maker. Additionally, general and administrative expenses, certain selling expenses, certain litigation settlements, and non-operating income and expenses are included in “Corporate and Other.” The Company does not report balance sheet information by segment since it is not reviewed by the Company’s chief operating decision maker. The accounting policies for the Company’s segments are the same as those described above in the discussion of "Revenue Recognition" and in the “Summary of Significant Accounting Policies” in the Company's Form 10-K for the year ended December 31, 2014. The Company has no inter-segment revenue.
	The tables below present segment information reconciled to total Company consolidated financial results, with segment operating income or loss including gross profit less direct research and development expenses and direct selling expenses as well as any litigation settlements, to the extent specifically identified by segment:
	(in $000’s)	Impax		Impax			Corporate			Total
	Three Months Ended March 31, 2015	Generics		Specialty			and Other			Company
				Pharma
	Revenues, net	$	128,741	$	14,355		$	---		$	143,096
	Cost of revenues		76,472		7,390			---			83,862
	Research and development		10,863		4,099			---			14,962
	Patent litigation expense		778		182			---			960
	Selling, general and administrative		4,286		14,856			31,018			50,160
	Income (loss) before provision for income taxes	$	36,342	$	(12,172	)	$	(34,875	)	$	(10,705	)
	(in $000’s)	Impax		Impax			Corporate			Total
	Three Months Ended March 31, 2014	Generics		Specialty			and Other			Company
				Pharma
	Revenues, net	$	109,141	$	9,577		$	---		$	118,718
	Cost of revenues		57,022		4,074			---			61,096
	Research and development		11,217		10,524			---			21,741
	Patent litigation expense		2,173		---			---			2,173
	Selling, general and administrative		2,383		9,221			13,873			25,477
	Income (loss) before provision for income taxes	$	36,346	$	(14,242	)	$	(13,474	)	$	8,630
	Foreign Operations
	The Company’s wholly owned subsidiary, Impax Laboratories (Taiwan) Inc., is constructing a manufacturing facility in Jhunan, Taiwan R.O.C. which is utilized for manufacturing, research and development, warehouse, and administrative functions, with approximately $131,368,000 of net carrying value of assets, composed principally of a building and equipment, included in the Company's consolidated balance sheet at March 31, 2015.

Note_18_Legal_and_Regulatory_M

Note 18 - Legal and Regulatory Matters	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block Supplement [Abstract]
Legal Matters and Contingencies [Text Block]	18. LEGAL AND REGULATORY MATTERS
	Patent Litigation
	There is substantial litigation in the pharmaceutical, biological, and biotechnology industries with respect to the manufacture, use, and sale of new products which are the subject of conflicting patent and intellectual property claims. One or more patents typically cover most of the brand name controlled release products for which the Company is developing generic versions.
	Under federal law, when a drug developer files an ANDA for a generic drug seeking approval before expiration of a patent, which has been listed with the FDA as covering the brand name product, the developer must certify its product will not infringe the listed patent(s) and/or the listed patent is invalid or unenforceable (commonly referred to as a “Paragraph IV” certification). Notices of such certification must be provided to the patent holder, who may file a suit for patent infringement within 45 days of the patent holder’s receipt of such notice. If the patent holder files suit within the 45 day period, the FDA can review and approve the ANDA, but is prevented from granting final marketing approval of the product until a final judgment in the action has been rendered in favor of the generic drug developer, or 30 months from the date the notice was received, whichever is sooner. Lawsuits have been filed against the Company in connection with the Company’s Paragraph IV certifications seeking an order delaying the approval of the Company’s ANDA until expiration of the patent(s) at issue in the litigation.
	Should a patent holder commence a lawsuit with respect to an alleged patent infringement by the Company, the uncertainties inherent in patent litigation make the outcome of such litigation difficult to predict. The delay in obtaining FDA approval to market the Company’s product candidates as a result of litigation, as well as the expense of such litigation, whether or not the Company is ultimately successful, could have a material adverse effect on the Company’s results of operations and financial position. In addition, there can be no assurance that any patent litigation will be resolved prior to the end of the 30-month period. As a result, even if the FDA were to approve a product upon expiration of the 30-month period, the Company may elect to not commence marketing the product if patent litigation is still pending.
	The Company is generally responsible for all of the patent litigation fees and costs associated with current and future products not covered by its alliance and collaboration agreements. The Company has agreed to share legal expenses with respect to third-party and Company products under the terms of certain of the alliance and collaboration agreements. The Company records the costs of patent litigation as expense in the period when incurred for products it has developed, as well as for products which are the subject of an alliance or collaboration agreement with a third-party.
	Although the outcome and costs of the asserted and unasserted claims is difficult to predict, the Company does not expect the ultimate liability, if any, for such matters to have a material adverse effect on its financial condition, results of operations, or cash flows.
	Patent Infringement Litigation
	Endo Pharmaceuticals Inc. and Grunenthal GmbH v. Impax Laboratories, Inc. and ThoRx Laboratories, Inc. (Oxymorphone hydrochloride); Endo Pharmaceuticals Inc. and Grunenthal GmbH v. Impax Laboratories, Inc. (Oxymorphone hydrochloride)
	In November 2012, Endo Pharmaceuticals, Inc. and Grunenthal GmbH (collectively, “Endo”) filed suit against ThoRx Laboratories, Inc., a wholly owned subsidiary of the Company (“ThoRx”), and the Company in the U.S. District Court for the Southern District of New York alleging patent infringement based on the filing of ThoRx’s ANDA relating to Oxymorphone hydrochloride, Extended Release tablets, 5, 7.5, 10, 15, 20, 30 and 40 mg, generic to Opana ER®. In January 2013, Endo filed a separate suit against the Company in the U.S. District Court for the Southern District of New York alleging patent infringement based on the filing of the Company’s ANDA relating to the same products. ThoRx and the Company filed an answer and counterclaims to the November 2012 suit and the Company filed an answer and counterclaims with respect to the January 2013 suit. A bench trial was completed in April 2015. No decision has been received. In November 2014, Endo Pharmaceuticals Inc. and Mallinckrodt LLC filed suit against the Company in the U.S. District Court for the District of Delaware making additional allegations of patent infringement based on the filing of the Company’s Oxymorphone hydrochloride ANDA described above. Also in November 2014, Endo and Mallinckrodt filed a separate suit in the U.S. District Court for the District of Delaware making additional allegations of patent infringement based on the filing of the ThoRx Oxymorphone hydrochloride ANDA described above. ThoRx and the Company filed an answer and counterclaim to those suits in which they are named as a defendant. The cases are currently pending.
	UCB Inc., et al. v. CorePharma LLC (Methylphenidate)
	In March 2014, UCB Inc. and UCB Manufacturing (collectively, “UCB”) filed suit against CorePharma LLC, a wholly-owned subsidiary of the Company, in the United States District Court for the District of New Jersey alleging patent infringement based on the filing of CorePharma’s ANDA relating to methylphenidate hydrochloride extended-release capsules, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg and 60 mg, generic to Metadate CD®. On May 27, 2014, CorePharma filed an answer and counterclaims. Discovery is proceeding. A trial date has not been set.
	Impax Laboratories Inc., et al. v. Lannett Holdings, Inc. and Lannett Company (Zomig®)
	In July 2014, the Company filed suit against Lannett Holdings, Inc. and Lannett Company (collectively, “Lannett”) in the United States District Court for the District of Delaware, alleging patent infringement based on the filing of the Lannett ANDA relating to Zolmitriptan Nasal Spray, 5mg, generic to Zomig® Nasal Spray. Lannett filed an answer and counterclaims alleging non-infringement and invalidity in September 2014, and the Company filed an answer to the counterclaims in October 2014. Discovery is proceeding, and trial is set for September 6, 2016.
	Shire LLC v. CorePharma LLC (Mixed Amphephetamines)
	In September 2014, Shire LLC (“Shire”) filed suit against CorePharma LLC, a wholly-owned subsidiary of the Company, in the United States District Court for the District of New Jersey alleging patent infringement based on the filing of CorePharma’s ANDA relating to dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, amphetamine sulfate extended-release capsules, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg, generic to Adderall XR®. On November 14, 2014, CorePharma filed an answer and counterclaims. Discovery is proceeding. A trial date has not been set.
	Other Litigation Related to the Company’s Business
	Civil Investigative Demand from the FTC (Minocycline Hydrochloride)
	On May 2, 2012, the Company received a Civil Investigative Demand (“CID”) from the United States Federal Trade Commission (“FTC”) concerning its investigation into the drug SOLODYN® and its generic equivalents. According to the FTC, the investigation relates to whether Medicis Pharmaceutical Corporation, now a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (“Medicis”), the Company, and six other companies have engaged or are engaged in unfair methods of competition in or affecting commerce by (i) entering into agreements regarding SOLODYN® or its generic equivalents and/or (ii) engaging in other conduct regarding the sale or marketing of SOLODYN® or its generic equivalents. The Company is cooperating with the FTC in producing documents, information and witnesses in response to the investigation. To the knowledge of the Company, no FTC proceedings have been initiated against the Company to date, however no assurance can be given as to the timing or outcome of this investigation.
	Solodyn® Antitrust Class Actions
	From July 2013 to April 2015, 15 class action complaints were filed against manufacturers of the brand drug Solodyn® and its generic equivalents, including the Company.
	On July 22, 2013, Plaintiff United Food and Commercial Workers Local 1776 & Participating Employers Health and Welfare Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the Eastern District of Pennsylvania on behalf of itself and others similarly situated.
	On July 23, 2013, Plaintiff Rochester Drug Co-Operative, Inc., a direct purchaser, filed a class action complaint in the United States District Court for the Eastern District of Pennsylvania on behalf of itself and others similarly situated.
	On August 1, 2013, Plaintiff International Union of Operating Engineers Local 132 Health and Welfare Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the Northern District of California on behalf of itself and others similarly situated. On August 29, 2013, this Plaintiff withdrew its complaint from the United States District Court for the Northern District of California, and on August 30, 2013, re-filed the same complaint in the United States Court for the Eastern District of Pennsylvania, on behalf of itself and others similarly situated.
	On August 9, 2013, Plaintiff Local 274 Health & Welfare Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the Eastern District of Pennsylvania on behalf of itself and others similarly situated.
	On August 12, 2013, Plaintiff Sheet Metal Workers Local No. 25 Health & Welfare Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the Eastern District of Pennsylvania on behalf of itself and others similarly situated.
	On August 27, 2013, Plaintiff Fraternal Order of Police, Fort Lauderdale Lodge 31, Insurance Trust Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the Eastern District of Pennsylvania on behalf of itself and others similarly situated.
	On August 29, 2013, Plaintiff Heather Morgan, an indirect purchaser, filed a class action complaint in the United States District Court for the Eastern District of Pennsylvania on behalf of itself and others similarly situated.
	On August 30, 2013, Plaintiff Plumbers & Pipefitters Local 178 Health & Welfare Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the Eastern District of Pennsylvania on behalf of itself and others similarly situated.
	On September 9, 2013, Plaintiff Ahold USA, Inc., a direct purchaser, filed a class action complaint in the United States District Court for the District of Massachusetts on behalf of itself and others similarly situated.
	On September 24, 2013, Plaintiff City of Providence, Rhode Island, an indirect purchaser, filed a class action complaint in the United States District Court for the District of Arizona on behalf of itself and others similarly situated.
	On October 2, 2013, Plaintiff International Union of Operating Engineers Stationary Engineers Local 39 Health & Welfare Trust Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the District of Massachusetts on behalf of itself and others similarly situated.
	On October 7, 2013, Painters District Council No. 30 Health and Welfare Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the District of Massachusetts on behalf of itself and others similarly situated.
	On October 25, 2013, Plaintiff Man-U Service Contract Trust Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the Eastern District of Pennsylvania on behalf of itself and others similarly situated.
	On March 13, 2014, Plaintiff Allied Services Division Welfare Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the District of Massachusetts on behalf of itself and others similarly situated.
	On March 19, 2014, Plaintiff NECA-IBEW Welfare Trust Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the District of Massachusetts on behalf of itself and others similarly situated.
	On February 25, 2014, the United States Judicial Panel on Multidistrict Litigation ordered the pending actions transferred to the District of Massachusetts for coordinated pretrial proceedings, as In Re Solodyn (Minocycline Hydrochloride) Antitrust Litigation.
	On March 26, 2015, Walgreen Co., The Kruger Co., Safeway Inc., HEB Grocery Company L.P., Albertson’s LLC, direct purchasers, filed a separate complaint in the United States District Court for the Middle District of Pennsylvania. On April 8, 2015, the Judicial Panel on Multi-District Litigation ordered the action be transferred to the District of Massachusetts, to be coordinated or consolidated with the coordinated proceedings.
	On April 16, 2015, Rite Aid Corporation and Rite Aid Hdqtrs. Corp, direct purchasers, filed a separate complaint in the United States District Court for the Middle District of Pennsylvania.
	The consolidated amended complaints allege that Medicis engaged in anticompetitive schemes by, among other things, filing frivolous patent litigation lawsuits, submitting frivolous Citizen Petitions, and entering into anticompetitive settlement agreements with several generic manufacturers, including the Company, to delay generic competition of Solodyn® and in violation of state and federal antitrust laws. Plaintiffs seek, among other things, unspecified monetary damages and equitable relief, including disgorgement and restitution. Oral argument on defendants’ motion to dismiss the consolidated amended complaints took place on March 12, 2015, and the motion remains under submission.
	Civil Investigative Demand from the FTC (Oxymorphone Hydrochloride)
	On February 25, 2014, the Company received a CID from the FTC concerning its investigation into the drug Opana® ER and its generic equivalents. According to the FTC, the investigation relates to whether Endo Pharmaceuticals, Inc. (“Endo”), the Company have engaged or are engaged in unfair methods of competition in or affecting commerce by (i) entering into agreements regarding Opana® ER or its generic equivalents and/or (ii) engaging in other conduct regarding the regulatory filings, sale or marketing of Opana® ER or its generic equivalents. The Company is cooperating with the FTC in producing documents, information and witnesses in response to the CID. To the knowledge of the Company, no proceedings by the FTC have been initiated against the Company at this time, however no assurance can be given as to the timing or outcome of this investigation.
	Opana ER® Antitrust Class Actions
	From June 2014 to April 2015, 14 class action complaints were filed against the manufacturer of the brand drug Opana ER® and the Company.
	On June 4, 2014, Plaintiff Fraternal Order of Police, Miami Lodge 20, Insurance Trust Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the Eastern District of Pennsylvania on behalf of itself and others similarly situated.
	On June 4, 2014, Plaintiff Rochester Drug Co-Operative, Inc., a direct purchaser, filed a class action complaint in the United States District Court for the Eastern District of Pennsylvania on behalf of itself and others similarly situated.
	On June 6, 2014, Plaintiff Value Drug Company, a direct purchaser, filed a class action complaint in the United States District Court for the Northern District of California on behalf of itself and others similarly situated. On June 26, 2014, this Plaintiff withdrew its complaint from the United States District Court for the Northern District of California, and on July 16, 2014, re-filed the same complaint in the United States District Court for the Northern District of Illinois, on behalf of itself and others similarly situated.
	On June 19, 2014, Plaintiff Wisconsin Masons’ Health Care Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the Northern District of Illinois on behalf of itself and others similarly situated.
	On July 17, 2014, Plaintiff Massachusetts Bricklayers, an indirect purchaser, filed a class action complaint in the United States District Court for the Eastern District of Pennsylvania on behalf of itself and others similarly situated.
	On August 11, 2014, Plaintiff Pennsylvania Employees Benefit Trust Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the Northern District of Illinois on behalf of itself and others similarly situated.
	On September 19, 2014, Plaintiff Meijer Inc., a direct purchaser, filed a class action complaint in the United States District Court for the Northern District of Illinois on behalf of itself and others similarly situated.
	On October 3, 2014, Plaintiff International Union of Operating Engineers, Local 138 Welfare Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the Northern District of Illinois on behalf of itself and others similarly situated.
	On November 17, 2014, Louisiana Health Service & Indemnity Company d/b/a Blue Cross and Blue Shield of Louisiana, an indirect purchaser, filed a class action complaint in the United Stated District Court for the Middle District of Louisiana on behalf of itself and others similarly situated.
	On December 19, 2014, Plaintiff Kim Mahaffay, an indirect purchaser, filed a class action complaint in the Superior Court of the State of California, Alameda County, on behalf of herself and others similarly situated. On January 27, 2015, the Defendants removed the action to the United States District Court for the Northern District of California.
	On January 12, 2015, Plaintiff Plumbers & Pipefitters Local 178 Health & Welfare Trust Fund, an indirect purchaser, filed a class action complaint in the United States District Court for the Northern District of Illinois on behalf of itself and others similarly situated.
	On December 12, 2014, the United States Judicial Panel on Multidistrict Litigation ordered the pending actions transferred to the Northern District of Illinois for coordinated pretrial proceedings, as In Re Opana ER Antitrust Litigation.
	On March 26, 2015 Walgreen Co., The Kruger Co., Safeway Inc., HEB Grocery Company L.P., Albertson’s LLC, direct purchasers, filed a separate complaint in the United States District Court for the Northern District of Illinois.
	On April 23, 2015, Rite Aid Corporation and Rite Aid Hdqtrs. Corp, direct purchasers, filed a separate complaint in the United States District Court for the Northern District of Illinois.
	In each case, the complaints allege that Endo engaged in an anticompetitive scheme by, among other things, entering into an anticompetitive settlement agreement with the Company to delay generic competition of Opana ER® and in violation of state and federal antitrust laws. Plaintiffs seek, among other things, unspecified monetary damages and equitable relief, including disgorgement and restitution. Consolidated amended complaints were filed on May 4, 2015.
	Civil Investigation Demand from the Attorney General of the State of Alaska
	On February 10, 2015, the Company received three CIDs from the Office of the Attorney General of the State of Alaska (“Alaska AG”) concerning its investigations into the drugs Adderall XR®, Effexor XR® and Opana® ER (each a “Product” and collectively, the “Products”) and their generic equivalents. According to the Alaska AG, the investigation is to determine whether the Company may have violated Alaskan state law by entering into settlement agreements with the respective brand name manufacturer for each of the foregoing Products that delayed generic entry of such Product into the marketplace.  The Company intends to cooperate with the Alaska AG in producing documents and information in response to the CIDs. To the knowledge of the Company, no proceedings have been initiated against the Company at this time, however no assurance can be given as to the timing or outcome of this investigation.
	United States Department of Justice Investigations
	Previously on November 6, 2014, the Company disclosed that one of its sales representatives received a grand jury subpoena from the Antitrust Division of the United States Justice Department (the "Justice Department"). In connection with this same investigation, on March 13, 2015, the Company received a grand jury subpoena from the Justice Department requesting the production of information and documents regarding the sales, marketing, and pricing of certain generic prescription medications. In particular, the Justice Department’s investigation currently focuses on four generic medications: digoxin tablets, terbutaline sulfate tablets, prilocaine/lidocaine cream, and calcipotriene topical solution. The Company has been cooperating and intends to continue cooperating with the investigation. However, no assurance can be given as to the timing or outcome of the investigation.
	Securities and Derivative Class Actions
On March 7, 2013 and April 8, 2013, two class action complaints were filed against the Company and certain current and former officers and directors of the Company in the United States District Court for the Northern District of California by Denis Mulligan, individually and on behalf of others similarly situated, and Haverhill Retirement System, individually and on behalf of others similarly situated, respectively (“Securities Class Actions”), alleging that the Company and those named officers and directors violated the federal securities law by making materially false and misleading statements and/or failed to disclose material adverse facts to the public in connection with manufacturing deficiencies at the Hayward, California manufacturing facility, including but not limited to the impact the deficiencies would have on the Company’s ability to gain approval from the FDA for the Company’s branded product candidate, RYTARY® and its generic version of Concerta®. These two Securities Class Actions were subsequently consolidated, assigned to the same judge, and lead plaintiff has been chosen. The plaintiff’s consolidated amended complaint was filed on September 13, 2013. The Company filed a motion to dismiss the consolidated amended complaint on November 14, 2013. On April 18, 2014, the Court denied the Company’s motion to dismiss. On September 22, 2014, the Company, together with certain current and former officers and directors of the Company, agreed to settle this consolidated securities class action, without any admission or concession of wrongdoing or liability by the Company or the other defendants. Pursuant to the settlement, the Company will pay $8.0 million for a full and complete release of all claims that were or could have been asserted against the Company or other defendants in this action. On January 16, 2015, the Court granted preliminary approval of the settlement. The Company will not be taking any charges for the settlement as the settlement amount will be paid for and covered by the Company's insurance policies. The settlement remains subject to final court approval and certain other conditions and does not resolve the related shareholder derivative litigations discussed below.
On March 19, 2013, Virender Singh, derivatively on behalf of the Company, filed a state court action against certain current and former officers and directors for breach of fiduciary duty and unjust enrichment in the Superior Court of the State of California County of Santa Clara, asserting similar allegations as those in the Securities Class Actions. On September 24, 2014, Nicholas Karant, derivatively on behalf of the Company, filed an action against certain current and former officers and directors in the United District Court for the Northern District of California, asserting similar allegations as those by Virender Singh. In addition, the Company is aware of two letters from stockholders demanding action by the Company’s board of directors, including to: (i) undertake an independent internal investigation into management’s alleged violations of Delaware and/or federal law; (ii) commence a civil action against members of management to recover damages sustained as a result of alleged breaches of fiduciary duties; and/or (iii) spearhead meaningful corporate reform to address alleged internal control inadequacies. Each letter further states that if such action is not commenced within a reasonable period of time, the stockholder will commence a stockholder’s derivative action on behalf of the Company.
On August 13, 2014, a class action complaint was filed against the Company and certain current and former officers and directors of the Company in the United States District Court for the Northern District of California by Linus Aruliah, individually and on behalf of all others similarly situated. The complaint alleged that the Company and those named officers and directors violated the federal securities laws by making materially false and misleading statements and/or failed to disclose material adverse facts to the public in connection with manufacturing deficiencies at the Company’s Taiwan manufacturing facility, including but not limited to the impact the deficiencies would have on the Company’s ability to gain approval from the FDA for the Company’s then branded product candidate, RYTARY® (which was subsequently approved by the FDA on January 7, 2015). On January 13, 2015, the Company, together with certain current and former officers and directors of the Company, agreed to settle this securities class action, without any admission or concession of wrongdoing or liability by the Company or the other defendants. Pursuant to the settlement, the Company will pay $4.75 million for a full and complete release of all claims that were or could have been asserted against the Company or other defendants in this action. The Company will not be taking any charges for the settlement as the settlement amount will be paid for and covered by the Company’s insurance policies. The settlement remains subject to preliminary and final court approval and certain other conditions and does not resolve the related shareholder derivative litigations.
On September 22, 2014, Randall Wickey, derivatively on behalf of the Company, filed an action against certain current and former officers and directors of the Company in the United States District for the Northern District of California, alleging breaches of fiduciary duty in connection with the Company’s response to various FDA notices and warnings regarding problems in the manufacturing and quality control processes at the Company’s Hayward, California and Taiwan manufacturing facilities. On November 10, 2014, International Union of Operating Engineers Local 478, derivatively on behalf of the Company, filed an action against certain current and former officers and directors of the Company in the United States District for the Northern District of California, asserting similar allegations as those by Randall Wickey. These two derivative actions were consolidated on February 5, 2015 and a consolidated complaint was filed on February 20, 2015.
Attorney General of the State of Connecticut Interrogatories and Subpoena Duces Tecum
On July 14, 2014, the Company received a subpoena and interrogatories (the “Subpoena”) from the State of Connecticut Attorney General (“Connecticut AG”) concerning its investigation into sales of the Company’s generic product, digoxin. According to the Connecticut AG, the investigation is to determine whether anyone engaged in a contract, combination or conspiracy in restraint of trade or commerce which has the effect of (i) fixing, controlling or maintaining prices or (ii) allocating or dividing customers or territories relating to the sale of digoxin in violation of Connecticut state antitrust law. The Company intends to cooperate with the Connecticut AG in producing documents and information in response to the Subpoena. To the knowledge of the Company, no proceedings by the Connecticut AG have been initiated against the Company at this time, however no assurance can be given as to the timing or outcome of this investigation.

Note_19_Supplementary_Financia

Note 19 - Supplementary Financial Information (unaudited)	3 Months Ended
	Mar. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information [Text Block]	19. SUPPLEMENTARY FINANCIAL INFORMATION (unaudited)
	Selected financial information for the quarterly period noted is as follows:
	(in $000’s except shares and per share amounts)	Quarter Ended
		31-Mar-15
	Revenue:
	Impax Generics sales, gross	$	355,321
	Less:
	Chargebacks		126,607
	Rebates		83,130
	Product Returns		6,427
	Other credits		13,198
	Impax Generics sales, net		125,959
	Rx Partner		2,239
	Other Revenues		543
	Impax Generics revenues, net		128,741
	Impax Specialty Pharma sales, gross		29,219
	Less:
	Chargebacks		5,561
	Rebates		2,132
	Product Returns		2,620
	Other credits		4,778
	Impax Specialty Pharma sales, net		14,128
	Other Revenues		227
	Impax Specialty Pharma revenues, net		14,355
	Total revenues		143,096
	Gross profit		59,234
	Net loss	$	(6,333	)
	Net loss per share (basic)	$	(0.09	)
	Net loss per share (diluted)	$	(0.09	)
	Weighted average common shares outstanding:
	Basic		68,967,875
	Diluted		68,967,875
	Selected financial information for the quarterly period noted is as follows:
	(in $000’s except shares and per share amounts)	Quarter Ended
		31-Mar-14
	Revenue:
	Impax Generics sales, gross	$	265,850
	Less:
	Chargebacks		95,714
	Rebates		52,054
	Product Returns		1,294
	Other credits		10,671
	Impax Generics sales, net		106,117
	Rx Partner		2,435
	Other Revenues		589
	Impax Generics revenues, net		109,141
	Impax Specialty Pharma sales, gross		20,643
	Less:
	Chargebacks		8,230
	Rebates		1,070
	Product Returns		181
	Other credits		1,853
	Impax Specialty Pharma sales, net		9,309
	Other Revenues		268
	Impax Specialty Pharma revenues, net		9,577
	Total revenues		118,718
	Gross profit		57,622
	Net income	$	6,425
	Net income per share (basic)	$	0.09
	Net income per share (diluted)	$	0.09
	Weighted average common shares outstanding:
	Basic		67,702,296
	Diluted		69,938,872

Note_20_Subsequent_Events

Note 20 - Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	20. SUBSEQUENT EVENTS
	On May 8, 2015, the Company received a Form 483 with three inspectional observations, following the FDA’s inspection of its Hayward manufacturing facility beginning from early April through early May 2015. During the inspection, the Company was also able to confirm that the FDA’s July 2014 inspection at the Hayward facility was officially classified as Voluntary Action Indicated (VAI). The 2015 inspection included a general cGMP inspection as well as pre approval inspections (PAI) for multiple pending products at the FDA. The FDA did not provide any status or classification to these observations and, pursuant to its established regulatory process, will defer classification until it has reviewed the Company’s response to each observation. The Company is currently working on its responses to the FDA regarding the observations. To date, the Company has not been informed by the FDA as to whether a satisfactory re-inspection of the Hayward manufacturing facility will be required to close out the warning letter and resolve the 2014 and 2015 Form 483 observations on the Hayward manufacturing facility.

Supplemental_Cash_Flow_Informa1

Supplemental Cash Flow Information (Tables)	3 Months Ended
	Mar. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]		Three Months Ended
	(in $000's)	March 31,		March 31,
		2015		2014
	Cash paid for interest	$	2,317	$	1
	Cash paid for income taxes	$	6,615	$	21,024

Note_4_Investments_Tables

Note 4 - Investments (Tables)	3 Months Ended
	Mar. 31, 2015
Investments Schedule [Abstract]
Held-to-maturity Securities [Table Text Block]	(in $000’s)	Amortized		Gross		Gross			Fair
	31-Dec-14	Cost		Unrecognized		Unrecognized			Value
				Gains		Losses
	Commercial paper	$	68,972	$	17	$	--		$	68,989
	Corporate bonds		131,011		--		(101	)		130,910
	Total short-term investments	$	199,983	$	17	$	(101	)	$	199,899

Note_5_Accounts_Receivable_Tab

Note 5 - Accounts Receivable (Tables)	3 Months Ended
	Mar. 31, 2015
Receivables [Abstract]
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	(in $000’s)	March 31,			December 31,
		2015			2014
	Gross accounts receivable	$	453,067		$	287,362
	Less: Rebate reserve		(188,548	)		(88,812	)
	Less: Chargeback reserve		(66,453	)		(43,125	)
	Less: Other deductions		(17,756	)		(8,935	)
	Accounts receivable, net	$	180,310		$	146,490
Allowance for Credit Losses on Financing Receivables [Table Text Block]	(in $000’s)	March 31,			December 31,
	Rebate reserve	2015			2014
	Beginning balance	$	88,812		$	88,449
	Acquired balances		78,226			--
	Provision recorded during the period		85,262			260,747
	Credits issued during the period		(63,752	)		(260,384	)
	Ending balance	$	188,548		$	88,812
	(in $000’s)	March 31,			December 31,
	Chargeback reserve	2015			2014
	Beginning balance	$	43,125		$	37,066
	Acquired balances		25,260			--
	Provision recorded during the period		132,168			487,377
	Credits issued during the period		(134,100	)		(481,318	)
	Ending balance	$	66,453		$	43,125

Note_6_Inventory_Tables

Note 6 - Inventory (Tables)	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	(in $000’s)	March 31,		December 31,
		2015		2014
	Raw materials	$	48,716	$	34,681
	Work in process		5,568		2,447
	Finished goods		77,982		55,102
	Total inventory		132,266		92,230
	Less: Non-current inventory		11,146		11,660
	Total inventory-current	$	121,120	$	80,570

Note_7_Property_Plant_and_Equi1

Note 7 - Property, Plant and Equipment (Tables)	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	(in $000’s)	March 31,			December 31,
		2015			2014
	Land	$	5,773		$	5,773
	Buildings and improvements		170,128			154,374
	Equipment		136,351			122,184
	Office furniture and equipment		14,352			12,623
	Construction-in-progress		10,494			9,404
	Property, plant and equipment, gross	$	337,098		$	304,358
	Less: Accumulated depreciation		(121,507	)		(116,189	)
	Property, plant and equipment, net	$	215,591		$	188,169

Note_8_Business_Acquisitions_T

Note 8 - Business Acquisitions (Tables)	3 Months Ended
	Mar. 31, 2015
Note 8 - Business Acquisitions (Tables) [Line Items]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Accounts receivable(1)	$	55,451
	Inventory		31,021
	Income tax receivable and other prepaid expenses		11,704
	Deferred income taxes		37,716
	Property, plant and equipment		27,539
	Intangible assets		727,600
	Assets held for sale		4,000
	Goodwill		124,476
	Other non-current assets		6,861
	Total assets assumed		1,026,368
	Current liabilities		61,595
	Other non-current liabilities		6,413
	Deferred tax liability		261,177
	Total liabilities assumed		329,185
	Cash paid, net of cash acquired	$	697,183
Schedule of Finite-Lived Intangible Assets [Table Text Block]	(in $000’s)	Initial				Accumulated			Impairment			Carrying
	31-Mar-15	Cost				Amortization						Value
	Amortized intangible assets:
	Tower currently marketed products	$	380,900			$	(2,804	)	$	---		$	378,096
	Tower in-process research and development		265,900				---			---			265,900
	Tower royalties and CMO relationships		80,800				---			---			80,800
	Zomig® product rights		41,783				(32,291	)		---			9,492
	Tolmar product rights		33,450				(11,351	)		(16,032	)		6,067
	Perrigo product rights		1,000				(334	)		---			666
	Ursodiol product rights		3,000				(496	)		---			2,504
	Other product rights		7,250				---			(750	)		6,500
	Total intangible assets	$	814,083			$	(47,276	)	$	(16,782	)	$	750,025
	(in $000’s)	Initial				Accumulated			Impairment			Carrying
	31-Dec-14	Cost				Amortization						Value
	Amortized intangible assets:
	Zomig® product rights	$	41,783			$	(31,561	)	$	---		$	10,222
	Tolmar product rights		33,450				(10,801	)		(16,032	)		6,617
	Perrigo product rights		1,000				(297	)		---			703
	Ursodiol product rights		3,000				(331	)		---			2,669
	Other product rights		7,250				---			(750	)		6,500
	Total intangible assets	$	86,483			$	(42,990	)	$	(16,782	)	$	26,711
Business Acquisition, Pro Forma Information [Table Text Block]		Three Months Ended
		March 31,
		2015				2014
	(in $000’s)
	Total revenues	$	175,533			$	174,067
	Net loss		(6,595	)			(12,679	)
Tower and Lineage [Member]
Note 8 - Business Acquisitions (Tables) [Line Items]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	(in $000’s)				Weighted Average
		Estimated Fair			Estimated Useful
		Value			Life (in years)
	Currently marketed products	$	380,900		13
	Royalties and contract manufacturing relationships		80,800		12
	In-process research and development		265,900		n/a
	Total intangible assets	$	727,600		12

Note_9_Goodwill_and_Intangible1

Note 9 - Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	(in $000’s)		Initial		Accumulated			Impairment			Carrying
	31-Mar-15		Cost		Amortization						Value
	Amortized intangible assets:
	Tower currently marketed products		$	380,900	$	(2,804	)	$	---		$	378,096
	Tower in-process research and development			265,900		---			---			265,900
	Tower royalties and CMO relationships			80,800		---			---			80,800
	Zomig® product rights			41,783		(32,291	)		---			9,492
	Tolmar product rights			33,450		(11,351	)		(16,032	)		6,067
	Perrigo product rights			1,000		(334	)		---			666
	Ursodiol product rights			3,000		(496	)		---			2,504
	Other product rights			7,250		---			(750	)		6,500
	Total intangible assets		$	814,083	$	(47,276	)	$	(16,782	)	$	750,025
	(in $000’s)		Initial		Accumulated			Impairment			Carrying
	31-Dec-14		Cost		Amortization						Value
	Amortized intangible assets:
	Zomig® product rights		$	41,783	$	(31,561	)	$	---		$	10,222
	Tolmar product rights			33,450		(10,801	)		(16,032	)		6,617
	Perrigo product rights			1,000		(297	)		---			703
	Ursodiol product rights			3,000		(331	)		---			2,669
	Other product rights			7,250		---			(750	)		6,500
	Total intangible assets		$	86,483	$	(42,990	)	$	(16,782	)	$	26,711
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	(in $000s)	Amortization
		Expense
	2015	$	38,887
	2016		35,986
	2017		32,723
	2018		37,922
	2019		35,845
	Thereafter		296,262
	Totals	$	477,625

Note_10_Accrued_Expenses_Commi1

Note 10 - Accrued Expenses, Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2015
Accrued Liabilities Disclosure [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	(in $000’s)	March 31,			December 31,
		2015			2014
	Payroll-related expenses	$	30,486		$	33,812
	Product returns		47,402			27,174
	Government rebates		30,470			18,272
	Legal and professional fees		13,484			9,497
	Income taxes payable		258			40
	Physician detailing sales force fees		2,545			2,336
	Litigation accrual		12,750			12,750
	Other		9,112			6,589
	Total accrued expenses	$	146,507		$	110,470
Schedule of Product Warranty Liability [Table Text Block]	(in $000’s)	March 31,			December 31,
	Returns Reserve	2015			2014
	Beginning balance	$	27,174		$	28,089
	Acquired balances		19,030			--
	Provision related to sales recorded in the period		9,047			12,016
	Credits issued during the period		(7,849	)		(12,931	)
	Ending balance	$	47,402		$	27,174

Note_14_Sharebased_Compensatio1

Note 14 - Share-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]		Three Months Ended
		March 31,
	(in $000’s)	2015			2014
	Manufacturing expenses	$	1,046		$	896
	Research and development		1,365			1,402
	Selling, general and administrative		4,077			2,088
	Total	$	6,488		$	4,386
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]		Number of			Weighted
		Shares			Average
		Under			Exercise
		Option			Price
					per Share
	Outstanding at December 31, 2014		3,042,180		$	14.78
	Options granted		335,750		$	40.66
	Options exercised		(216,008	)	$	12.04
	Options forfeited		--		$	--
	Outstanding at March 31, 2015		3,161,922		$	17.72
	Options exercisable at March 31, 2015		2,460,957		$	12.91
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	Restricted Stock Awards	Number of			Weighted
		Restricted			Average
		Stock Awards			Grant Date
					Fair Value
	Non-vested at December 31, 2014		2,327,176		$	23.61
	Granted		210,660		$	39.09
	Vested		(26,066	)	$	21.89
	Forfeited		(29,681	)	$	24.4
	Non-vested at March 31, 2015		2,482,089		$	24.93

Note_16_Earnings_Per_Share_Tab

Note 16 - Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]		Three Months Ended
		March 31,
	(in $000’s except share and per share amounts)	2015			2014
	Numerator:
	Net (loss) income	$	(6,333	)	$	6,425
	Denominator:
	Weighted average common shares outstanding		68,967,875			67,702,296
	Effect of dilutive stock options and restricted stock awards		--			2,236,576
	Diluted weighted average common shares outstanding		68,967,875			69,938,872
	Basic net (loss) income per share	$	(0.09	)	$	0.09
	Diluted net (loss) income per share	$	(0.09	)	$	0.09

Note_17_Segment_Information_Ta

Note 17 - Segment Information (Tables)	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	(in $000’s)	Impax		Impax			Corporate			Total
	Three Months Ended March 31, 2015	Generics		Specialty			and Other			Company
				Pharma
	Revenues, net	$	128,741	$	14,355		$	---		$	143,096
	Cost of revenues		76,472		7,390			---			83,862
	Research and development		10,863		4,099			---			14,962
	Patent litigation expense		778		182			---			960
	Selling, general and administrative		4,286		14,856			31,018			50,160
	Income (loss) before provision for income taxes	$	36,342	$	(12,172	)	$	(34,875	)	$	(10,705	)
	(in $000’s)	Impax		Impax			Corporate			Total
	Three Months Ended March 31, 2014	Generics		Specialty			and Other			Company
				Pharma
	Revenues, net	$	109,141	$	9,577		$	---		$	118,718
	Cost of revenues		57,022		4,074			---			61,096
	Research and development		11,217		10,524			---			21,741
	Patent litigation expense		2,173		---			---			2,173
	Selling, general and administrative		2,383		9,221			13,873			25,477
	Income (loss) before provision for income taxes	$	36,346	$	(14,242	)	$	(13,474	)	$	8,630

Note_19_Supplementary_Financia1

Note 19 - Supplementary Financial Information (unaudited) (Tables)	3 Months Ended
	Mar. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information [Table Text Block]	(in $000’s except shares and per share amounts)	Quarter Ended
		31-Mar-15
	Revenue:
	Impax Generics sales, gross	$	355,321
	Less:
	Chargebacks		126,607
	Rebates		83,130
	Product Returns		6,427
	Other credits		13,198
	Impax Generics sales, net		125,959
	Rx Partner		2,239
	Other Revenues		543
	Impax Generics revenues, net		128,741
	Impax Specialty Pharma sales, gross		29,219
	Less:
	Chargebacks		5,561
	Rebates		2,132
	Product Returns		2,620
	Other credits		4,778
	Impax Specialty Pharma sales, net		14,128
	Other Revenues		227
	Impax Specialty Pharma revenues, net		14,355
	Total revenues		143,096
	Gross profit		59,234
	Net loss	$	(6,333	)
	Net loss per share (basic)	$	(0.09	)
	Net loss per share (diluted)	$	(0.09	)
	Weighted average common shares outstanding:
	Basic		68,967,875
	Diluted		68,967,875
	(in $000’s except shares and per share amounts)	Quarter Ended
		31-Mar-14
	Revenue:
	Impax Generics sales, gross	$	265,850
	Less:
	Chargebacks		95,714
	Rebates		52,054
	Product Returns		1,294
	Other credits		10,671
	Impax Generics sales, net		106,117
	Rx Partner		2,435
	Other Revenues		589
	Impax Generics revenues, net		109,141
	Impax Specialty Pharma sales, gross		20,643
	Less:
	Chargebacks		8,230
	Rebates		1,070
	Product Returns		181
	Other credits		1,853
	Impax Specialty Pharma sales, net		9,309
	Other Revenues		268
	Impax Specialty Pharma revenues, net		9,577
	Total revenues		118,718
	Gross profit		57,622
	Net income	$	6,425
	Net income per share (basic)	$	0.09
	Net income per share (diluted)	$	0.09
	Weighted average common shares outstanding:
	Basic		67,702,296
	Diluted		69,938,872

Supplemental_Cash_Flow_Informa2

Supplemental Cash Flow Information (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Supplemental Cash Flow Elements [Abstract]
Accrued Vendor Invoices	$1,326,000	$4,165,000
Depreciation	$5,381,000	$4,973,000

Supplemental_Cash_Flow_Informa3

Supplemental Cash Flow Information (Details) - Supplemental Disclosure of Non-cash Investing and Financing Activities (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Supplemental Disclosure of Non-cash Investing and Financing Activities [Abstract]
Cash paid for interest	$2,317	$1
Cash paid for income taxes	$6,615	$21,024

Note_1_The_Company_Basis_of_Pr1

Note 1 - The Company & Basis of Presentation (Details) (USD $)	0 Months Ended		3 Months Ended
In Millions, unless otherwise specified	Mar. 09, 2015	Oct. 08, 2014	Mar. 31, 2015
Note 1 - The Company & Basis of Presentation (Details) [Line Items]
Number of Reportable Segments			2
Number Of Channels			4
Number of Internally Developed Branded Pharmaceutical Product Candidate			1
Prohealth Biotech [Member]
Note 1 - The Company & Basis of Presentation (Details) [Line Items]
Equity Method Investment, Ownership Percentage			57.54%
California [Member]
Note 1 - The Company & Basis of Presentation (Details) [Line Items]
Number Of Properties			5
Hayward California [Member]
Note 1 - The Company & Basis of Presentation (Details) [Line Items]
Number Of Leased Properties			3
Tower and Lineage [Member]
Note 1 - The Company & Basis of Presentation (Details) [Line Items]
Business Combination, Consideration Transferred (in Dollars)	$700	$700
Supplemental Unemployment Benefits, Severance Benefits (in Dollars)			2.4
Business Combination, Number of Positions Eliminated			10
Severance Costs (in Dollars)			$0.10

Note_2_Revenue_Recognition_Det

Note 2 - Revenue Recognition (Details)	3 Months Ended
	Mar. 31, 2015
Note 2 - Revenue Recognition (Details) [Line Items]
Cash Discount Discount Rate	2.00%
Period Prior to Expiration Date [Member]
Note 2 - Revenue Recognition (Details) [Line Items]
Product Return Period	6 months
Period Following Expiration Date [Member]
Note 2 - Revenue Recognition (Details) [Line Items]
Product Return Period	12 months
Minimum [Member]
Note 2 - Revenue Recognition (Details) [Line Items]
Cash Discount Invoice Terms	30 days
Maximum [Member]
Note 2 - Revenue Recognition (Details) [Line Items]
Cash Discount Invoice Terms	90 days

Note_4_Investments_Details

Note 4 - Investments (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Investments Schedule [Abstract]
Held-to-maturity Securities, Fair Value	$0	$199,899,000

Note_4_Investments_Details_Sum

Note 4 - Investments (Details) - Summary of Short-term Investments (USD $)	Mar. 31, 2015	Dec. 31, 2014
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost		$199,983,000
Gross Unrecognized Gains		17,000
Gross Unrecognized Losses		-101,000
Fair Value	0	199,899,000
Commercial Paper [Member]
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost		68,972,000
Gross Unrecognized Gains		17,000
Fair Value		68,989,000
Corporate Bond Securities [Member]
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost		131,011,000
Gross Unrecognized Losses		-101,000
Fair Value		$130,910,000

Note_5_Accounts_Receivable_Det

Note 5 - Accounts Receivable (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Receivables [Abstract]
Allowance for Doubtful Accounts Receivable, Current	$926,000	$515,000

Note_5_Accounts_Receivable_Det1

Note 5 - Accounts Receivable (Details) - Composition of Accounts Receivable, Net (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Composition of Accounts Receivable, Net [Abstract]
Gross accounts receivable	$453,067	$287,362
Less: Rebate reserve	-188,548	-88,812
Less: Chargeback reserve	-66,453	-43,125
Less: Other deductions	-17,756	-8,935
Accounts receivable, net	$180,310	$146,490

Note_5_Accounts_Receivable_Det2

Note 5 - Accounts Receivable (Details) - Roll Forward of the Rebate and Chargeback Reserves Activity (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Financing Receivable, Allowance for Credit Losses [Line Items]
Ending balance	$66,453	$43,125
Ending balance	188,548	88,812
Rebate Reserve [Member]
Financing Receivable, Allowance for Credit Losses [Line Items]
Beginning balance	88,812	88,449
Acquired balances	78,226
Provision recorded during the period	85,262	260,747
Credits issued during the period	-63,752	-260,384
Ending balance	188,548	88,812
Chargeback Reserve [Member]
Financing Receivable, Allowance for Credit Losses [Line Items]
Provision recorded during the period	132,168	487,377
Credits issued during the period	-134,100	-481,318
Ending balance	66,453	43,125
Beginning balance	43,125	37,066
Acquired balances	$25,260

Note_6_Inventory_Details

Note 6 - Inventory (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Mar. 09, 2015
Note 6 - Inventory (Details) [Line Items]
Inventory Valuation Reserves	31,473,000	$25,639,000
Unapproved Inventory [Member]
Note 6 - Inventory (Details) [Line Items]
Unapproved Product Inventory Net	5,934,000	7,312,000
Raw Materials [Member]
Note 6 - Inventory (Details) [Line Items]
Inventory Turnover Period Minimum	3 years
Inventory Turnover Period Maximum	5 years
Finished Goods [Member]
Note 6 - Inventory (Details) [Line Items]
Inventory Turnover Period Maximum	2 years
Other Noncurrent Assets [Member] | Tower and Lineage [Member]
Note 6 - Inventory (Details) [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory			3,000,000
Tower and Lineage [Member]
Note 6 - Inventory (Details) [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	31,021,000		$34,000,000

Note_6_Inventory_Details_Inven

Note 6 - Inventory (Details) - Inventory, Net of Carrying Value Reserves (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Inventory, Net of Carrying Value Reserves [Abstract]
Raw materials	$48,716	$34,681
Work in process	5,568	2,447
Finished goods	77,982	55,102
Total inventory	132,266	92,230
Less: Non-current inventory	11,146	11,660
Total inventory-current	$121,120	$80,570

Note_7_Property_Plant_and_Equi2

Note 7 - Property, Plant and Equipment (Details) (Tower and Lineage [Member], USD $)	Mar. 31, 2015	Mar. 09, 2014
In Thousands, unless otherwise specified
Tower and Lineage [Member]
Note 7 - Property, Plant and Equipment (Details) [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	$27,539	$27,500

Note_7_Property_Plant_and_Equi3

Note 7 - Property, Plant and Equipment (Details) - Property, Plant and Equipment, Net (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Property, Plant and Equipment, Net [Abstract]
Land	$5,773	$5,773
Buildings and improvements	170,128	154,374
Equipment	136,351	122,184
Office furniture and equipment	14,352	12,623
Construction-in-progress	10,494	9,404
Property, plant and equipment, gross	337,098	304,358
Less: Accumulated depreciation	-121,507	-116,189
Property, plant and equipment, net	$215,591	$188,169

Note_8_Business_Acquisitions_D

Note 8 - Business Acquisitions (Details) (USD $)	3 Months Ended		0 Months Ended		6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 09, 2015	Oct. 08, 2014	Dec. 31, 2014
Note 8 - Business Acquisitions (Details) [Line Items]
Goodwill	$152,050,000				$27,574,000
Fair Value Adjustment to Inventory [Member] | Tower and Lineage [Member]
Note 8 - Business Acquisitions (Details) [Line Items]
Assets, Fair Value Adjustment	1,000,000	4,000,000
Impax Specialty Pharma [Member] | Tower and Lineage [Member]
Note 8 - Business Acquisitions (Details) [Line Items]
Goodwill			38,000,000
Impax Specialty Pharma [Member]
Note 8 - Business Acquisitions (Details) [Line Items]
Goodwill	38,000,000
Impax Generics [Member] | Tower and Lineage [Member]
Note 8 - Business Acquisitions (Details) [Line Items]
Goodwill			86,000,000
Impax Generics [Member]
Note 8 - Business Acquisitions (Details) [Line Items]
Goodwill	114,000,000
General and Administrative Expense [Member] | Tower and Lineage [Member]
Note 8 - Business Acquisitions (Details) [Line Items]
Business Combination, Acquisition Related Costs			6,000,000
Wells Fargo Bank, N.A. [Member] | Tower and Lineage [Member] | Term Loan [Member]
Note 8 - Business Acquisitions (Details) [Line Items]
Long-term Debt	435,000,000		435,000,000
Line of Credit Facility, Commitment Fee Amount	2,300,000
Tower and Lineage [Member] | Revolving Credit Facility [Member]
Note 8 - Business Acquisitions (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity			50,000,000
Tower and Lineage [Member]
Note 8 - Business Acquisitions (Details) [Line Items]
Business Combination, Consideration Transferred			700,000,000	700,000,000
Business Combination, Cash Acquired and Other Working Capital Adjustments			39,000,000
Long-term Debt			435,000,000
Business Combination, Acquisition Related Costs	12,000,000		9,000,000		4,000,000
Cash Acquired from Acquisition			41,000,000
Business Combination, Acquired Receivables, Fair Value			55,000,000
Business Combination, Acquired Receivables, Estimated Uncollectible			9,000,000
Goodwill	124,476,000		124,000,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual	14,000,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual	-5,000,000
Severance and Retention Costs	$3,000,000
Currently Marketed Products [Member]
Note 8 - Business Acquisitions (Details) [Line Items]
Fair Value Inputs, Discount Rate			15.00%
In Process Research and Development [Member]
Note 8 - Business Acquisitions (Details) [Line Items]
Fair Value Inputs, Discount Rate			16.00%

Note_8_Business_Acquisitions_D1

Note 8 - Business Acquisitions (Details) - Fair Values of Tangible and Identifiable Intangible Assets Acquired and Liabilities Assumed (USD $)	3 Months Ended
	Mar. 31, 2015		Dec. 31, 2014	Mar. 09, 2015	Mar. 09, 2014
Note 8 - Business Acquisitions (Details) - Fair Values of Tangible and Identifiable Intangible Assets Acquired and Liabilities Assumed [Line Items]
Goodwill	$152,050,000		$27,574,000
Cash paid, net of cash acquired	697,183,000
Tower and Lineage [Member]
Note 8 - Business Acquisitions (Details) - Fair Values of Tangible and Identifiable Intangible Assets Acquired and Liabilities Assumed [Line Items]
Accounts receivable(1)	55,451,000	[1]
Inventory	31,021,000			34,000,000
Income tax receivable and other prepaid expenses	11,704,000
Deferred income taxes	37,716,000
Property, plant and equipment	27,539,000				27,500,000
Intangible assets	727,600,000
Assets held for sale	4,000,000
Goodwill	124,476,000			124,000,000
Other non-current assets	6,861,000
Total assets assumed	1,026,368,000
Current liabilities	61,595,000
Other non-current liabilities	6,413,000
Deferred tax liability	261,177,000
Total liabilities assumed	329,185,000
Cash paid, net of cash acquired	$697,183,000
[1]	The accounts receivable acquired in the Transaction had a fair value of approximately $55 million, including an allowance for doubtful accounts of approximately $9 million, which represents the Company's best estimate on March 9, 2015 (the closing date of the Transaction) of the contractual cash flows not expected to be collected by the acquired companies in the Transaction.

Note_8_Business_Acquisitions_D2

Note 8 - Business Acquisitions (Details) - Acquired Intangible Assets (Tower and Lineage [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Estimated Fair Value	$727,600
Intangible Assets, Average Estimated Useful Life (years)	12 years
Currently Marketed Products [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Estimated Fair Value	380,900
Intangible Assets, Average Estimated Useful Life (years)	13 years
Royalties and Contract Manufacturing Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Estimated Fair Value	80,800
Intangible Assets, Average Estimated Useful Life (years)	12 years
In Process Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Estimated Fair Value	$265,900

Note_8_Business_Acquisitions_D3

Note 8 - Business Acquisitions (Details) - The Unaudited Condensed Pro Forma Consolidated Statements of Operations (Tower and Lineage [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Tower and Lineage [Member]
Note 8 - Business Acquisitions (Details) - The Unaudited Condensed Pro Forma Consolidated Statements of Operations [Line Items]
Total revenues	$175,533	$174,067
Net loss	($6,595)	($12,679)

Note_9_Goodwill_and_Intangible2

Note 9 - Goodwill and Intangible Assets (Details) (USD $)	3 Months Ended		1 Months Ended	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Jun. 30, 2012	Sep. 30, 2013	Jun. 30, 2014	Dec. 31, 2014	Mar. 09, 2015
Note 9 - Goodwill and Intangible Assets (Details) [Line Items]
Goodwill	$152,050,000					$27,574,000
Impairment of Intangible Assets (Excluding Goodwill)		2,876,000
Impairment of Intangible Assets (Excluding Goodwill), Percent of Carrying Value		100.00%
Amortization of Intangible Assets	4,286,000	2,430,000
Products Approved [Member] | Tolmar Incorporated [Member]
Note 9 - Goodwill and Intangible Assets (Details) [Line Items]
Number Of Products	10		10
Product Pending Approval [Member] | Tolmar Incorporated [Member]
Note 9 - Goodwill and Intangible Assets (Details) [Line Items]
Number Of Products	1		1
Abbreviated New Drug Applications [Member] | Research and Development Expense [Member]
Note 9 - Goodwill and Intangible Assets (Details) [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)				800,000
Impax Generics [Member] | Tower and Lineage [Member]
Note 9 - Goodwill and Intangible Assets (Details) [Line Items]
Goodwill							86,000,000
Impax Generics [Member]
Note 9 - Goodwill and Intangible Assets (Details) [Line Items]
Goodwill	114,000,000
Impax Specialty Pharma [Member] | Tower and Lineage [Member]
Note 9 - Goodwill and Intangible Assets (Details) [Line Items]
Goodwill							38,000,000
Impax Specialty Pharma [Member]
Note 9 - Goodwill and Intangible Assets (Details) [Line Items]
Goodwill	38,000,000
Cost of Sales [Member]
Note 9 - Goodwill and Intangible Assets (Details) [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)		2,900,000		13,200,000
Minimum [Member] | Tolmar Product Rights [Member]
Note 9 - Goodwill and Intangible Assets (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	5 years
Maximum [Member] | Tolmar Product Rights [Member]
Note 9 - Goodwill and Intangible Assets (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	12 years
Tower and Lineage [Member]
Note 9 - Goodwill and Intangible Assets (Details) [Line Items]
Goodwill	124,476,000						124,000,000
Goodwill, Acquired During Period	124,500,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	727,600,000
Actavis Product Rights [Member]
Note 9 - Goodwill and Intangible Assets (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	8 years
Tolmar Incorporated [Member]
Note 9 - Goodwill and Intangible Assets (Details) [Line Items]
Number Of Products	11		11
Zomig Product Rights Tablet [Member]
Note 9 - Goodwill and Intangible Assets (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	14 months
Zomig Product Rights Orally Disintegrating Tablet [Member]
Note 9 - Goodwill and Intangible Assets (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	11 months
Zomig Product Rights Nasal Spray [Member]
Note 9 - Goodwill and Intangible Assets (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	72 months
Perrigo Product Rights [Member]
Note 9 - Goodwill and Intangible Assets (Details) [Line Items]
Finite-Lived Intangible Assets, Period Increase (Decrease)					$1,000,000

Note_9_Goodwill_and_Intangible3

Note 9 - Goodwill and Intangible Assets (Details) - Intangible Assets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Amortized intangible assets:
Initial cost	$814,083	$86,483
Accumulated amortization	-47,276	-42,990
Impairment	-16,782	-16,782
Carrying value	750,025	26,711
Other Product Rights [Member]
Amortized intangible assets:
Initial cost	7,250	7,250
Impairment	-750	-750
Carrying value	6,500	6,500
Currently Marketed Products [Member]
Amortized intangible assets:
Initial cost	380,900
Accumulated amortization	-2,804
Carrying value	378,096
In Process Research and Development [Member]
Amortized intangible assets:
Initial cost	265,900
Carrying value	265,900
Royalties and Contract Manufacturing Relationships [Member]
Amortized intangible assets:
Initial cost	80,800
Carrying value	80,800
Zomig Product Rights [Member]
Amortized intangible assets:
Initial cost	41,783	41,783
Accumulated amortization	-32,291	-31,561
Carrying value	9,492	10,222
Tolmar Product Rights [Member]
Amortized intangible assets:
Initial cost	33,450	33,450
Accumulated amortization	-11,351	-10,801
Impairment	-16,032	-16,032
Carrying value	6,067	6,617
Perrigo Product Rights [Member]
Amortized intangible assets:
Initial cost	1,000	1,000
Accumulated amortization	-334	-297
Carrying value	666	703
Ursodiol Product Rights [Member]
Amortized intangible assets:
Initial cost	3,000	3,000
Accumulated amortization	-496	-331
Carrying value	$2,504	$2,669

Note_9_Goodwill_and_Intangible4

Note 9 - Goodwill and Intangible Assets (Details) - Expected Amortization Expense (USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Expected Amortization Expense [Abstract]
2015	$38,887
2016	35,986
2017	32,723
2018	37,922
2019	35,845
Thereafter	296,262
Totals	$477,625

Note_10_Accrued_Expenses_Commi2

Note 10 - Accrued Expenses, Commitments and Contingencies (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Note 10 - Accrued Expenses, Commitments and Contingencies (Details) [Line Items]
Estimated Litigation Liability, Current	$12,750,000	$12,750,000
Contractual Obligation	495,000
Purchase Order Commitments	72,007,000
Purchase Commitment Period	1 year
Prepaid Expenses and Other Current Assets [Member]
Note 10 - Accrued Expenses, Commitments and Contingencies (Details) [Line Items]
Insurance Settlements Receivable, Current	$12,750,000

Note_10_Accrued_Expenses_Commi3

Note 10 - Accrued Expenses, Commitments and Contingencies (Details) - Accrued Expenses (USD $)	Mar. 31, 2015	Dec. 31, 2014
Accrued Expenses [Abstract]
Payroll-related expenses	$30,486,000	$33,812,000
Product returns	47,402,000	27,174,000
Government rebates	30,470,000	18,272,000
Legal and professional fees	13,484,000	9,497,000
Income taxes payable	258,000	40,000
Physician detailing sales force fees	2,545,000	2,336,000
Litigation accrual	12,750,000	12,750,000
Other	9,112,000	6,589,000
Total accrued expenses	$146,507,000	$110,470,000

Note_10_Accrued_Expenses_Commi4

Note 10 - Accrued Expenses, Commitments and Contingencies (Details) - Roll Forward of Product Return Reserve (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Product Warranty Liability [Line Items]
Ending balance	$47,402	$27,174
Returns Reserve [Member]
Product Warranty Liability [Line Items]
Beginning balance	27,174	28,089
Acquired balances	19,030
Provision related to sales recorded in the period	9,047	12,016
Credits issued during the period	-7,849	-12,931
Ending balance	$47,402	$27,174

Note_11_Income_Taxes_Details

Note 11 - Income Taxes (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Expense (Benefit)	($4,372,000)	$2,205,000
Effective Income Tax Rate Reconciliation, Percent	41.00%	26.00%

Note_12_Debt_Details

Note 12 - Debt (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Mar. 09, 2015	Feb. 11, 2015	Jan. 02, 2015
Note 12 - Debt (Details) [Line Items]
Senior Secured Leverage Ratio	3.5
Accrued Liabilities, Current	$146,507,000	$110,470,000
Long-term Debt, Current Maturities	18,741,000
Long-term Debt, Excluding Current Maturities	398,609,000
Debt Instrument, Unamortized Discount, Current	3,000,000
Debt Instrument, Unamortized Discount, Noncurrent	14,700,000
Interest Expense [Member] | Wells Fargo Bank, N.A. [Member] | Senior Secured [Member]
Note 12 - Debt (Details) [Line Items]
Amortization of Debt Discount (Premium)	200,000
Wells Fargo Bank, N.A. [Member] | Accrued Interest Expense on Debt [Member] | Senior Secured [Member]
Note 12 - Debt (Details) [Line Items]
Accrued Liabilities, Current	1,500,000
Wells Fargo Bank, N.A. [Member] | Tower and Lineage [Member] | Senior Secured [Member] | Revolving Credit Facility [Member]
Note 12 - Debt (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity			50,000,000
Wells Fargo Bank, N.A. [Member] | Tower and Lineage [Member] | Term Loan [Member]
Note 12 - Debt (Details) [Line Items]
Long-term Debt	435,000,000		435,000,000
Wells Fargo Bank, N.A. [Member] | Prior Credit Facility [Member] | Revolving Credit Facility [Member]
Note 12 - Debt (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity				50,000,000
Long-term Line of Credit				0
Wells Fargo Bank, N.A. [Member] | Senior Secured [Member]
Note 12 - Debt (Details) [Line Items]
Debt Instrument, Unamortized Discount	17,800,000
Interest Expense, Debt	2,300,000
Wells Fargo Bank, N.A. [Member] | Term Loan [Member]
Note 12 - Debt (Details) [Line Items]
Debt Instrument, Amortization, Percentage of Principal Amount	1.25%
Debt Instrument, Interest Rate, Increase (Decrease)	0.25%
Wells Fargo Bank, N.A. [Member] | Revolver [Member] | Revolving Credit Facility [Member]
Note 12 - Debt (Details) [Line Items]
Long-term Line of Credit	0
Wells Fargo Bank, N.A. [Member] | Revolver [Member]
Note 12 - Debt (Details) [Line Items]
Letters of Credit Outstanding, Amount	10,000,000
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.50%
Required Percent of Certain Asset Sales and Debt Issuances to Pay Down Outstanding Borrowings	100.00%
Required Percent of Excess Cash Flow to Pay Down Outstanding Borrowings	75.00%
Debt Instrument, Unused Borrowing Capacity, Fee	11,000
Wells Fargo Bank, N.A. [Member] | Revolving Credit Facility [Member]
Note 12 - Debt (Details) [Line Items]
Commitment Fee Rate Increase (Decrease)	0.13%
Wells Fargo Bank, N.A. [Member]
Note 12 - Debt (Details) [Line Items]
Debt Instrument, Debt Default Trigger					25,000,000
Tower and Lineage [Member] | Revolving Credit Facility [Member]
Note 12 - Debt (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity			50,000,000
Tower and Lineage [Member]
Note 12 - Debt (Details) [Line Items]
Long-term Debt			$435,000,000

Note_13_Alliance_and_Collabora1

Note 13 - Alliance and Collaboration Agreements (Details) (USD $)

3 Months Ended

1 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

1 Months Ended

25 Months Ended

1 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Jun. 30, 2012

Dec. 31, 2012

Dec. 31, 2014

Dec. 31, 2011

Dec. 31, 2013

Mar. 31, 2011

Dec. 31, 2009

Mar. 31, 2009

Dec. 31, 2008

Jun. 30, 2010

Mar. 31, 2011

Aug. 31, 2013

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Research and Development Expense

$14,962,000

$21,741,000

Products Approved [Member] | Tolmar Incorporated [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Number Of Products

10

10

Product Pending Approval [Member] | Tolmar Incorporated [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Number Of Products

1

1

Products in Development [Member] | Tolmar Incorporated [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Number Of Products

2

Research and Development Expense

1,550,000

Diclofenac Sodium Gel [Member] | Milestone Payments [Member] | Tolmar Incorporated [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Collaborative Arrangement Required Payment Net

2,000,000

Generic Products [Member] | Valeant [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Number Of Products

4

1

Branded Advanced Form of Solodyn Product [Member] | Valeant [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Number Of Products

1

Milestone Payments [Member] | Tolmar Incorporated [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Collaborative Arrangement Required Payment Net

1,000,000

12,000,000

Research and Development Expense

1,000,000

Milestone Payments [Member] | Valeant [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Collaborative Arrangement Maximum Contingent Payments Amount

8,000,000

Collaborative Arrangement Contingent Payments Received And Potentially To Be Received

3,000,000

2,000,000

5,000,000

Milestone Payments [Member] | Endo Pharmaceuticals Incorporation [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Collaborative Arrangement Maximum Contingent Payments Amount

30,000,000

Up-front Payment Arrangement [Member] | Valeant [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Collaborative Arrangement Contingent Payments Received And Potentially To Be Received

40,000,000

Up-front Payment Arrangement [Member] | Endo Pharmaceuticals Incorporation [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Deferred Revenue, Additions

10,000,000

Milestone Payment Arrangement [Member] | Valeant [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Collaborative Arrangement Contingent Payments Received And Potentially To Be Received

15,000,000

Clinical Milestone Events [Member] | Endo Pharmaceuticals Incorporation [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Collaborative Arrangement Maximum Contingent Payments Amount

15,000,000

Regulatory Milestone Events [Member] | Endo Pharmaceuticals Incorporation [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Collaborative Arrangement Maximum Contingent Payments Amount

5,000,000

Commercialization Events [Member] | Endo Pharmaceuticals Incorporation [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Collaborative Arrangement Maximum Contingent Payments Amount

10,000,000

Tolmar Incorporated [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Maximum Loan Amount Pursuant to Loan and Security Agreement

15,000,000

Loans Receivable, Net

15,000,000

IND-enabling Animal Studies for New Development Candidate [Member] | Minimum [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

12 months

IND-enabling Animal Studies for New Development Candidate [Member] | Maximum [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

18 months

Phase 1 Trials [Member] | Minimum [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

1 year

Phase 1 Trials [Member] | Maximum [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

2 years

Phase 2 Trials [Member] | Minimum [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

1 year

Phase 2 Trials [Member] | Maximum [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

3 years

Phase 3 Trials [Member] | Minimum [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

2 years

Phase 3 Trials [Member] | Maximum [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

4 years

Bioequivalence Studies [Member] | Minimum [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

3 months

Bioequivalence Studies [Member] | Maximum [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

1 year

Preparation And Submission Of Regulatory Filings [Member] | Minimum [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

6 months

Preparation And Submission Of Regulatory Filings [Member] | Maximum [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

12 months

Acceptance Of Regulatory Filings For Substantive Review [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

2 months

Potential Marketing Approval One [Member] | Minimum [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

1 year

Potential Marketing Approval One [Member] | Maximum [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

3 years

Potential Marketing Approval Two [Member] | Minimum [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

1 year

Potential Marketing Approval Two [Member] | Maximum [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Completion Period

3 years

Minimum [Member] | Tolmar Product Rights [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Finite-Lived Intangible Asset, Useful Life

5 years

Maximum [Member] | Tolmar Product Rights [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Finite-Lived Intangible Asset, Useful Life

12 years

Specified Threshold [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Product Sales

100,000,000

Shire Laboratories Incorporated [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Accounts Payable, Other

5,834,000

4,447,000

Tolmar Incorporated [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Accounts Payable, Other

7,540,000

2,961,436

Number Of Products

11

11

Collaborative Arrangement Up Front Payment

21,000,000

Collaborative Arrangement Maximum Contingent Payments Amount

10,000,000

Teva Pharmaceutical Industries Limited [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Collaborative Arrangement Maximum Contingent Payments Amount

3,000,000

Service Agreement Term

10 years

Pfizer Incorporated [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Service Agreement Term

15 years

Valeant [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Number Of Products

5

Astra Zeneca [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Collaborative Arrangement Quarterly Payments Made

43,564,000

Finite-Lived Intangible Assets, Gross

45,096,000

Prepaid Royalties

41,340,000

Accrued Royalties

4,025,000

2,615,000

Endo Pharmaceuticals Incorporation [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Collaborative Arrangement Copromotion Service Fee Percentage

100.00%

Deferred Revenue Estimated Period Of Recognition

112 months

Deferred Revenue

4,083,000

DURECT Corporation [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Collaborative Arrangement Up Front Payment

2,000,000

Collaborative Arrangement Maximum Contingent Payments Amount

61,000,000

Product Acquisition Agreement with Teva [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Collaborative Arrangement Maximum Contingent Payments Amount

3,500,000

RiconPharma [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Collaborative Arrangement Maximum Contingent Payments Amount

500,000

Incentive Cash Payment

225,000

Micro Labs Limited [Member]

Note 13 - Alliance and Collaboration Agreements (Details) [Line Items]

Collaborative Arrangement Maximum Contingent Payments Amount

$750,000

Note_14_Sharebased_Compensatio2

Note 14 - Share-based Compensation (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Note 14 - Share-based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)	$56,450,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 32 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in Shares)	2,799,227
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value (in Dollars)	4,221,000	3,789,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value (in Dollars)	$571,000	$621,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)	2,190,892
Stock Options and Restricted Stock Awards [Member] | Minimum [Member]
Note 14 - Share-based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years
Stock Options and Restricted Stock Awards [Member] | Maximum [Member]
Note 14 - Share-based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Stock Options and Restricted Stock Awards [Member]
Note 14 - Share-based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Restricted Stock [Member] | Minimum [Member]
Note 14 - Share-based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years
Restricted Stock [Member] | Maximum [Member]
Note 14 - Share-based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Restricted Stock [Member]
Note 14 - Share-based Compensation (Details) [Line Items]
Share Based Compensation Arrangement by Share-based Payment Award Equity Instruments Other ThanOptions Vested and Expected to Vest Outstanding, Number (in Shares)	2,197,376

Note_14_Sharebased_Compensatio3

Note 14 - Share-based Compensation (Details) - Share-based Compensation Expense (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	$6,488	$4,386
Manufacturing Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	1,046	896
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	1,365	1,402
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	$4,077	$2,088

Note_14_Sharebased_Compensatio4

Note 14 - Share-based Compensation (Details) - Summary of Stock Option Activity (USD $)	3 Months Ended
	Mar. 31, 2015
Summary of Stock Option Activity [Abstract]
Number of Shares, Options Outstanding	3,042,180
Weighted-Average Exercise Price per Share, Options Outstanding	$14.78
Options exercisable at March 31, 2015	2,460,957
Options exercisable at March 31, 2015	$12.91
Options granted	335,750
Options granted	$40.66
Options exercised	-216,008
Options exercised	$12.04
Options forfeited	0
Options forfeited	$0
Number of Shares, Options Outstanding	3,161,922
Weighted-Average Exercise Price per Share, Options Outstanding	$17.72

Note_14_Sharebased_Compensatio5

Note 14 - Share-based Compensation (Details) - Summary of Non-vested Restricted Stock Awards (Restricted Stock Awards [Member], USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Restricted Stock Awards [Member]
Note 14 - Share-based Compensation (Details) - Summary of Non-vested Restricted Stock Awards [Line Items]
Restricted Stock Awards, Non-vested	2,482,089	2,327,176
Weighted-Average Grant Date Fair Value, Non-vested	$24.93	$23.61
Granted	210,660
Granted	$39.09
Vested	-26,066
Vested	$21.89
Forfeited	-29,681
Forfeited	$24.40

Note_15_Stockholders_Equity_De

Note 15 - Stockholders' Equity (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014
Stockholders' Equity Note [Abstract]
Preferred Stock, Shares Authorized	2,000,000	2,000,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)	$0.01	$0.01
Preferred Stock, Shares Issued	0		0
Common Stock, Shares Authorized	90,000,000	90,000,000
Common Stock, Par or Stated Value Per Share (in Dollars per share)	$0.01	$0.01

Note_16_Earnings_Per_Share_Det

Note 16 - Earnings Per Share (Details)	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	331,500

Note_16_Earnings_Per_Share_Det1

Note 16 - Earnings Per Share (Details) - Reconciliation of Basic and Diluted Earnings Per Share (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Reconciliation of Basic and Diluted Earnings Per Share [Abstract]
Net (loss) income (in Dollars)	($6,333)	$6,425
Weighted average common shares outstanding	68,967,875	67,702,296
Effect of dilutive stock options and restricted stock awards		2,236,576
Diluted weighted average common shares outstanding	68,967,875	69,938,872
Basic net (loss) income per share (in Dollars per share)	($0.09)	$0.09
Diluted net (loss) income per share (in Dollars per share)	($0.09)	$0.09

Note_17_Segment_Information_De

Note 17 - Segment Information (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Note 17 - Segment Information (Details) [Line Items]
Number of Reportable Segments	2
Number of Internally Developed Branded Pharmaceutical Product Candidate	1
Assets (in Dollars)	$1,782,263,000	$1,079,197,000
Taiwan Facility [Member]
Note 17 - Segment Information (Details) [Line Items]
Assets (in Dollars)	$131,368,000

Note_17_Segment_Information_De1

Note 17 - Segment Information (Details) - Segment Information Reconciled to Consolidated Financial Results (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Segment Reporting Information [Line Items]
Revenues, net	$143,096,000	$118,718,000
Cost of revenues	83,862,000	61,096,000
Research and development	14,962,000	21,741,000
Patent litigation expense	960,000	2,173,000
Selling, general and administrative	50,160,000	25,477,000
Income (loss) before provision for income taxes	-10,705,000	8,630,000
Impax Generics [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues, net	128,741,000	109,141,000
Cost of revenues	76,472,000	57,022,000
Research and development	10,863,000	11,217,000
Patent litigation expense	778,000	2,173,000
Selling, general and administrative	4,286,000	2,383,000
Income (loss) before provision for income taxes	36,342,000	36,346,000
Impax Generics [Member]
Segment Reporting Information [Line Items]
Revenues, net	128,741,000	109,141,000
Impax Specialty Pharma [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues, net	14,355,000	9,577,000
Cost of revenues	7,390,000	4,074,000
Research and development	4,099,000	10,524,000
Patent litigation expense	182,000
Selling, general and administrative	14,856,000	9,221,000
Income (loss) before provision for income taxes	-12,172,000	-14,242,000
Impax Specialty Pharma [Member]
Segment Reporting Information [Line Items]
Revenues, net	14,355,000	9,577,000
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative	31,018,000	13,873,000
Income (loss) before provision for income taxes	($34,875,000)	($13,474,000)

Note_18_Legal_and_Regulatory_M1

Note 18 - Legal and Regulatory Matters (Details) (USD $)	3 Months Ended	22 Months Ended	11 Months Ended	0 Months Ended	1 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Apr. 30, 2015	Apr. 30, 2015	Jan. 13, 2015	Apr. 08, 2013
Note 18 - Legal and Regulatory Matters (Details) [Line Items]
Loss Contingency Patent Infringement Litigation Period Within Which Patent Holder May File Suit For Patent Infringement	45 days
Loss Contingency Patent Infringement Litigation Maximum Stay Period For Approval Of Abbreviated New Drug Application	30 months
Subsequent Event [Member] | Solodyn [Member]
Note 18 - Legal and Regulatory Matters (Details) [Line Items]
Number of Class Action Complaints		15
Subsequent Event [Member] | Opana ER [Member]
Note 18 - Legal and Regulatory Matters (Details) [Line Items]
Number of Class Action Complaints			14
Securities Class Actions [Member]
Note 18 - Legal and Regulatory Matters (Details) [Line Items]
Number of Class Action Complaints					2
Litigation Settlement, Amount (in Dollars)	-8			($4.75)

Note_19_Supplementary_Financia2

Note 19 - Supplementary Financial Information (unaudited) (Details) - Selected Financial Information (USD $)	3 Months Ended		12 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Less:
Impax Generics revenues, net	$143,096	$118,718
Gross profit	59,234	57,622
Net income	-6,333	6,425
Net income per share (basic) (in Dollars per share)	($0.09)	$0.09
Net income per share (diluted) (in Dollars per share)	($0.09)	$0.09
Weighted average common shares outstanding:
Basic (in Shares)	68,967,875	67,702,296
Diluted (in Shares)	68,967,875	69,938,872
Impax Generics [Member] | Chargeback Reserve [Member]
Less:
Chargebacks	126,607	95,714
Impax Generics [Member] | Rebate Reserve [Member]
Less:
Chargebacks	83,130	52,054
Impax Generics [Member] | Other Credits [Member]
Less:
Chargebacks	13,198	10,671
Impax Generics [Member] | Rx Partner [Member]
Less:
Other	2,239	2,435
Impax Generics [Member] | Other Revenues [Member]
Less:
Other	543	589
Impax Generics [Member]
Revenue:
Impax Generics sales, gross	355,321	265,850
Less:
Product Returns	6,427	1,294
Impax Generics sales, net	125,959	106,117
Impax Generics revenues, net	128,741	109,141
Impax Specialty Pharma [Member] | Chargeback Reserve [Member]
Less:
Chargebacks	5,561	8,230
Impax Specialty Pharma [Member] | Rebate Reserve [Member]
Less:
Chargebacks	2,132	1,070
Impax Specialty Pharma [Member] | Other Credits [Member]
Less:
Chargebacks	4,778	1,853
Impax Specialty Pharma [Member] | Other Revenues [Member]
Less:
Other		268
Impax Specialty Pharma [Member]
Revenue:
Impax Generics sales, gross	29,219	20,643
Less:
Product Returns	2,620	181
Impax Generics sales, net	14,128	9,309
Other	227
Impax Generics revenues, net	14,355	9,577
Chargeback Reserve [Member]
Less:
Chargebacks	132,168		487,377
Rebate Reserve [Member]
Less:
Chargebacks	$85,262		$260,747